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Abstract 
Influenza A viruses pose a significant threat to public health. Seasonal circulation of influenza viruses 
causes significant morbidity and mortality each year, despite wide-spread seasonal vaccination. Influenza 
viruses continually acquire substitutions in the viral membrane protein hemagglutinin (HA), the primary 
target of human immunity, thus allowing viruses to escape vaccine-induced immunity through a process 
called antigenic drift. Additionally, pandemic influenza strains occasionally enter the human population 
that we do not have vaccines against. To address this problem, universal influenza vaccines that target 
the conserved HA stalk domain are currently being developed. In this dissertation we explore the 
protective capacity of antibodies that target the HA stalk domain and the durability of this domain as a 
vaccine target. We used human serological cohorts to demonstrate for the first time that HA stalk 
antibodies are associated with protection against influenza infection and severe disease. In addition, we 
used a humanized mouse model to demonstrate the in vivo protection of HA stalk antibodies against 
severe influenza disease. We next determined that the HA stalk domain is acquiring amino acid 
substitutions and assessed the antigenic effect of these substitutions using a human serological cohort. 
We demonstrate that these substitutions do not reduce binding of HA stalk antibodies in polyclonal 
human sera, suggesting this domain has not experienced antigenic drift during the past decade of 
seasonal circulation. Overall, the work presented here identifies a potential correlate of protection that 
can be used for HA stalk-based universal influenza vaccine trials and establishes the HA stalk domain as 
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Influenza A viruses pose a significant threat to public health. Seasonal circulation of 
influenza viruses causes significant morbidity and mortality each year, despite wide-
spread seasonal vaccination. Influenza viruses continually acquire substitutions in the viral 
membrane protein hemagglutinin (HA), the primary target of human immunity, thus 
allowing viruses to escape vaccine-induced immunity through a process called antigenic 
drift. Additionally, pandemic influenza strains occasionally enter the human population that 
we do not have vaccines against. To address this problem, universal influenza vaccines 
that target the conserved HA stalk domain are currently being developed. In this 
dissertation we explore the protective capacity of antibodies that target the HA stalk 
domain and the durability of this domain as a vaccine target. We used human serological 
cohorts to demonstrate for the first time that HA stalk antibodies are associated with 
protection against influenza infection and severe disease. In addition, we used a 
humanized mouse model to demonstrate the in vivo protection of HA stalk antibodies 
against severe influenza disease. We next determined that the HA stalk domain is 
acquiring amino acid substitutions and assessed the antigenic effect of these substitutions 
using a human serological cohort. We demonstrate that these substitutions do not reduce 
binding of HA stalk antibodies in polyclonal human sera, suggesting this domain has not 
experienced antigenic drift during the past decade of seasonal circulation. Overall, the 
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work presented here identifies a potential correlate of protection that can be used for HA 
stalk-based universal influenza vaccine trials and establishes the HA stalk domain as a 
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Section 1.1 - A global perspective 
Just over 100 years ago, the greatest recorded pandemic in human history 
ravaged the world: the 1918 ‘Spanish’ Influenza. This novel influenza virus made the leap 
into human circulation from an animal reservoir, initiating three pandemic waves which 
resulted in an estimated 50-100 million deaths worldwide – a greater loss of human life 
than even the First World War [1, 2]. Since 1918, the viral descendants of this pandemic 
influenza strain have continued to circulate in humans, undergoing reassortment with 
other influenza strains and causing four additional pandemics over the past century. 
Modern seasonal influenza strains still contain genes that can be traced back to the 1918 
ancestral influenza strain [3]. 
Influenza epidemics occur each year, despite widespread vaccination efforts. 
Seasonal influenza vaccine effectiveness is highly variable, ranging from 19-60% efficacy 
over the past decade, with previous years seeing efficacy as low as 10% [4]. Additionally, 
annual vaccination does not provide long-term protection, in part due to the ability of 
influenza virus to evade host immune responses [5]. While it is difficult to estimate the 
incidence of influenza infection worldwide due to limited surveillance in some regions, the 
CDC estimates that during the 2017-2018 influenza season approximately 45 million 
influenza infections occurred in the US alone, resulting in about 810,000 hospitalizations 
and 61,000 deaths [6]. Additionally, the Burden of Communicable Diseases in Europe 
project recently completed a study to assess the impact of infectious diseases on 
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population health within the European Union; of the 31 infectious diseases examined 
(including HIV and tuberculosis), influenza infection was ranked highest, generating about 
30% of the total disease burden [7].  
While the estimates of disease burden are alarming, of greater concern is the 
possibility of a pandemic influenza strain entering the human population. The emergence 
of a pandemic influenza strain would dramatically increase morbidity and mortality rates 
around the world, and precipitate unprecedented economic burden. The 
interconnectedness of individuals on the planet has been a large determinant in the spread 
of influenza viruses and their subsequent epidemics and pandemics throughout history. 
During the 1918 influenza pandemic, the high density population of military barracks 
provided efficient transmission conditions for influenza viruses, while large-scale 
movement of military troops continually carried the emerging pandemic strain to naïve 
populations [8]. Accelerated international travel for business, commerce, and tourism has 
been associated with the rapid spread of influenza viruses, including the 2009 H1N1 
pandemic strain (pH1N1) [9]; indeed, a person can now fly to any major urban center in 
the world within the incubation period of influenza virus [10]. The impact of an influenza 
pandemic would be felt in the world economy as well. In 2007 the World Bank estimated 
a cost of about three trillion dollars if a severe H5N1 pandemic were to occur [11]. 
Considering the frequency of travel and pace of society today, the world is especially 
vulnerable to a new influenza pandemic. It is thus imperative to examine lessons from the 
past to learn what factors contributed to the emergence of pandemic strains and to 
aggressively pursue all avenues for prevention.  
In this chapter I will introduce influenza A viruses, the human immune response to 
influenza infection and vaccination, and the evolutionary arms race that takes place 
between the virus and host’s immune system. Finally, I will discuss the current state of 
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influenza vaccines and the efforts that are currently being made to improve seasonal 
vaccine effectiveness and to provide protection against pandemic influenza strains. 
Section 1.2 - Influenza A virus: tropism, structure, and replication 
The Orthomyxoviridae family of viruses includes several Influenza genera, though 
only Influenza A (IAV) and Influenza B (IBV) circulate in humans [12]. Aquatic birds are 
the primary reservoir for influenza A viruses [13]. Avian IAVs infect the epithelial cells of 
the gastrointestinal tract and are transmitted via the fecal-oral route [13]. In contrast, 
human IAVs are transmitted via the respiratory route, where the epithelial cells of the 
airway and lung are infected [14]. Influenza infection, and subsequent immune cell 
infiltration, cause lung inflammation and alveolar epithelial injury that can eventually lead 
to failure of gas exchange [15, 16]. The considerable lung trauma caused by IAV infection 
may ultimately lead to acute respiratory distress syndrome (ARDS) or even death [17, 18]. 
IAVs are enveloped with a segmented, negative-sense, single stranded RNA 
(ssRNA) genome of approximately 14 kilobases [19]. The eight ssRNA genomic segments 
of IAV are associated with viral proteins; the RNA segments are coated in nucleoprotein 
(NP) [20], while the heterotrimeric viral RNA polymerase (PB1, PB2, and PA) binds the 
ends of the viral RNA [21]. The viral ribonucleoprotein (vRNP) complex is coated by the 
M1 matrix protein [22], which is in turn enveloped by the host-cell derived lipid membrane 
layer. The viral membrane is decorated with glycoprotein spikes of hemagglutinin (HA) 
and neuraminidase (NA) in a ratio of about 4:1 [23], as well as a small number of matrix 
ion channels (M2) that span the lipid membrane (M2:HA ratio of about 1:100-1000) [24].  
Influenza A viruses are categorized according to the identity of their cognate HA and NA 
proteins [25], which can be subtyped into at least 18 HA and 11 NA serotypes [26-28]. The 
18 HAs can be further categorized into two genetically and antigenically distinct groups 
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[29, 30], with group 1 containing H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, and 
H18, whereas group 2 encompasses H3, H4, H7, H10, H14, and H15 (Figure 1.1). The 
sequence homology within a single HA subtype is estimated to be greater than 90%, 
between subtypes in a single group is about 60-74%, and between groups the homology 
drops to about 40-44% [31-33]. 
 
The HA protein forms a homotrimer of ~250 kDa [34, 35] that contains two distinct 
functional domains: the membrane distal head and the membrane proximal stalk (Figure 
1.2). The HA head mediates attachment of influenza virions to the host cell by binding to 
glycan structures containing a terminal sialic acid through the receptor-binding site [36, 
37]. The linkage of the glycan structure’s terminal sialic acid is considered to be a 
determinant of host species specificity, with avian viruses characterized by binding α2,3-
linked sialic acid and mammalian viruses typically binding α2,6-linked sialic acid [38-52]. 
The HA preference for sialic acid linkage is directed in part by structural features within 
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the receptor binding site, and 
is thought to correlate with 
receptor availability within 
the host species [16, 53, 54]. 
The HA stalk domain 
contains the fusion peptide 
buried within the 
hydrophobic core of the 
globular HA protein [55, 56]. Membrane fusion is triggered by decreasing pH within the 
endosome as virions are trafficked into the host cell. When the pH reaches ~5.5-5.0 [57], 
the HA protein undergoes a dramatic conformational change: the HA1 membrane distal 
domains retain their pH-neutral structure but dissociate from each other [58-60], while the 
fusion peptides in the HA stalk domain are transferred to the membrane-distal region after 
loop-to-helix (AAs 55 and 76) and helix-to-loop (AAs 106 and 112) transitions within HA2 
[56]. This conformational rearrangement is required for viral-endosomal membrane fusion 
and subsequent entry of the viral genome into the host cytoplasm [61-64].   
Once membrane fusion occurs, the vRNP is transported into the host nucleus 
where transcription is initiated with the viral RNA polymerase [65]. Newly synthesized 
mRNAs are used for translation of viral proteins, followed by synthesis of first 
complementary RNA (cRNA), then viral RNA (vRNA) that is subsequently coated in NP 
and M1 [66]. The newly synthesized viral proteins and vRNA are then trafficked to the 
apical membrane of polarized host epithelial cells, where assembly and budding of 
nascent virus occurs [66]. As the nascent HA and NA proteins are trafficked to the cell 
surface they are post-translationally modified by host cell machinery to achieve their final 
glycosylated and fully mature structures [66].  
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To produce an infectious virion capable of membrane fusion, the immature HA 
(HA0) protein must be cleaved into HA1 and HA2 subunits that are linked by disulfide 
bonds [67-69]. The host proteases that can cleave HA0 are determinants of viral 
replication sites, as they are only expressed in certain tissues, such as the mucosa of the 
gastrointestinal and respiratory tracts [70]. Human IAVs encode for a monobasic cleavage 
site in the HA0 protein that can be processed by several different cellular proteases found 
in human respiratory epithelial cells, including transmembrane protease serine S-1 
member 2 (TMPRSS2) and human airway trypsin-like protease (HAT) [71, 72]. TMPRSS2 
is expressed in the trans-Golgi network, where it can cleave the HA0 protein as it is 
trafficked to the cellular membrane. The M2 ion channel may assist in the prevention of 
premature activation of the mature, fusogenic HA protein by equilibrating the slightly acidic 
pH of the Golgi network [73, 74]. HAT is localized to the cellular membrane, where it can 
cleave HA0 on nascent virions as they bud from the infected host cell [75, 76]. Conversely, 
highly pathogenic avian IAVs contain a multibasic cleavage site that can be cleaved 
intracellularly in the trans-Golgi compartment by proteases such as furin [77]; the 
ubiquitous expression of these intracellular proteases contributes to a systemic, lethal 
infection with up to a 100% mortality rate in poultry [78, 79]. 
As the nascent IAVs bud from the cell surface, their release is dependent upon the 
sialidase activity of NA. The NA protein is a homotetramer with a membrane-distal globular 
head domain [80] that contains a catalytic tyrosine residue within a highly conserved active 
site on each monomer [81]. NA removes the terminal sialic acid from cell surface glycans 
through hydrolysis of the glycosidic linkage [82-84]; this action facilitates the release of 
budding viruses by preventing HA from binding to sialic acid at the cell surface [85, 86]. 
NAs encoded by human IAVs appear to have a general preference for α2,3-linked sialic 
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acid and variable abilities to cleave α2,6-linked sialic acid [80, 87, 88]; however, in-depth 
studies of NA sialic acid preferences are still lacking. 
 
Section 1.3 - Human immune responses to influenza infection 
The human immune response to influenza infection is a highly interconnected and 
complex system, making it impossible to examine a single component without 
consideration of many influential factors. Here, I will briefly cover the highlights of the 
innate immune response and contributions of CD8+ and CD4+ T cells to protection against 
IAV infection. I will then go into greater detail about the activation of B cells and production 
of high-affinity, IAV-specific antibodies. 
Innate immunity 
The innate immune system acts as the first line of defense against IAV infection. 
Human respiratory epithelial cells detect pathogen associated molecular patterns 
(PAMPs), such as IAV RNA, through a variety of receptors. Detection of PAMPs initiates 
signaling pathways that lead to the secretion of type I and type III interferons (IFNs), pro-
inflammatory cytokines, eicosanoids, and chemokines. Type I IFNs induce the expression 
of hundreds of IFN-stimulated genes to aid in protecting neighboring cells form infection 
[89-96]. The pro-inflammatory cytokines and eicosanoids induce inflammation, fever, and 
influence the adaptive immune response. Secreted chemokines work to recruit myeloid 
and lymphoid cells, such as neutrophils and natural killer (NK) cells, to the site of infection 
to aid in the clearance of virus-infected cells to inhibit viral replication and spread [97, 98].  
Dendritic cells (DCs), located within the respiratory tract and secondary lymphoid 
tissues [99, 100], act as the bridge between the innate and adaptive immune responses. 
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Antigen-loaded DCs migrate to secondary lymphoid structures where they activate naïve 
T cells and promote a polarized T helper 1 (TH1) cell response through the secretion of IL-
12 [101]. The characteristic TH1 cytokine, IFN-γ, acts on DCs to further enhance antigen 
presentation during the T cell priming process [102] and upregulation of MHC class II 
expression [103]. The TH1 polarization mediated by DCs has other downstream effects 
important for responding to influenza virus infection, including induction of antibody 
isotype-switching [104, 105]. 
CD8+ T cells 
Naïve CD8+ T cells are activated by DCs in the draining lymph node, leading to 
proliferation and differentiation into cytolytic CD8+ T cells. Activated CD8+ T cells then 
migrate back to the lungs where they induce apoptosis in IAV-infected cells through potent 
cytolytic responses [106]. Although CD8+ T cells cannot prevent an infection from 
occurring, they do play a crucial role in the control of, and recovery from, influenza infection 
[107-109]. Memory CD8+ T cells are capable of heterosubtypic protection upon 
subsequent infection, as they typically target epitopes in the more conserved internal IAV 
proteins [110, 111]. This cross-reactivity offers the potential for broad immunity against 
diverse influenza strains as long as the established memory CD8+ T cell population 
survives. Murine models have demonstrated lifetime persistence of influenza-specific 
CD8+ T cells [112, 113], and recent studies in humans have detected epitope-specific 
CD8+ T cells by ex vivo tetramer staining over a 13-year time period [114]. 
CD4+ T cells 
Similar to CD8+ T cells, influenza-specific naïve CD4+ T cells interact with antigen-
presenting DCs in secondary lymphoid tissues. Activated CD4+ T cells proliferate and 
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begin to differentiate, acquiring effector functions and producing cytokines to direct other 
immune functions. In primary influenza infections, CD4+ T cells indirectly mediate viral 
clearance by promoting antibody production by B cells [115-118] and enhancing 
recruitment of naïve CD8+ T cells to the lymph node [119] for interaction with antigen-
loaded DCs [120, 121]. CD4+ T cells are important in the priming and establishment of 
the memory CD8+ T cell compartment [122]. Additionally, memory CD4+ T cells likely play 
a role in the recruitment of early innate effector cells to the lung [123, 124], promoting 
effector mechanisms to blunt the early stages of IAV infection and replication [125]. Finally, 
a cytolytic subset of CD4+ T cells are enriched in lung tissue during influenza infection 
[126-130], suggesting functional CD4+ T cells may also mediate direct control of viral 
replication and spread in the respiratory tract. 
B cells 
The humoral adaptive immune response is essential for protection against 
reinfection by a multitude of pathogens, each with their own unique molecular structures 
that must be recognized for appropriate response and subsequent protection. The 
adaptive immune response of vertebrates combats this daunting molecular diversity of 
pathogens with a comparable level of diversity amongst antibodies. B cells express 
antibodies that are composed of heavy and light chains that are randomly assembled 
through a genetic rearrangement process called VDJ recombination, generating 
tremendous structural diversity [131]. Mature B cells express B cell receptors (BCRs) on 
their cell surface that are encoded for by these rearranged antibody gene segments. 
During an immune response to influenza infection, B cells specific for influenza antigens 
are activated by the interaction between their BCR and cognate antigen. B cells encounter 
influenza antigens in specialized lymphoid structures called germinal centers that are 
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present in the lymph nodes and spleen [132]. CD4+ T cells are also present in these 
germinal centers and provide help to activated B cells to undergo proliferation, class-
switching, and somatic hypermutation of the variable region of the heavy and light chain 
genes to generate variants. These B cell variants then undergo clonal selection by 
competing for antigen binding through a process called affinity maturation, resulting in a 
high-affinity polyclonal antibody response [133]. These high-affinity, class-switched B cells 
can go on to become long-lived plasma cells or memory B cells. During a secondary 
immune response, memory B cells can be recalled and undergo additional rounds of 
somatic hypermutation and affinity maturation [134]. Recruitment of influenza-specific 
memory B cells during secondary immune responses has important ramifications for 
antibody-mediated immunity, which will be discussed in detail later. 
Antibodies 
All IAV proteins are potential targets for a protective antibody response, but not all 
are easily accessible to antibodies. HA and NA are present on both viral membranes and 
the surface of infected cells, making them the most abundant and easily accessible targets 
[135]. Typically, HA induces the largest antibody response, with about 25-52% of 
plasmablasts binding to HA after an infection, while NA accounts for about 14-35% of IAV-
induced plasmablasts [136]. Anti-NA antibodies can block the enzymatic cleavage of sialic 
acid by NA [136], a function that is required for IAVs to successfully infiltrate mucosal 
surfaces and for the release of nascent viruses as they bud from cells [137]. NA antibodies 
have demonstrated protection against IAV lethal challenge in animal models [138-140], 
can prevent transmission of virus in guinea pigs [141], and are associated with protection 
in human field and challenge studies [142, 143]. In addition to the viral membrane proteins, 
internal IAV proteins, such as NP, may become accessible to antibodies when they are 
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displayed on the membrane of an infected cell, or after an infected cell has died [144]. 
Non-neutralizing antibodies targeting NP have been identified as contributing to protection 
against lethal influenza infections in mice [145].  
The HA protein is the major target of neutralizing antibodies and is the focus of this 
thesis. Therefore, the remainder of this chapter will focus exclusively on the HA protein 
and HA-specific antibody-mediated protection. Antibodies targeting the HA head have 
historically been the hallmark for measuring vaccine efficacy and levels of pre-existing 
immunity in the human population [146]. Additionally, by interacting with their innate 
cellular partners, some HA stalk-specific antibodies mediate broad, cross-subtype and 
cross-group protection against IAVs [147, 148]. 
HA Head Antibodies 
The HA head domain is the immunodominant target for antibodies elicited by IAV 
infection and vaccination. Antibodies that target the HA head can prevent IAV entry into 
the host cell by binding at or near the receptor binding site (RBS). Antibodies binding within 
or near the RBS can block virus binding to sialic acid and/or prevent receptor-mediated 
endocytosis [149-151]. Antibodies elicited against the HA head domain are usually strain-
specific, and therefore only confer homosubtypic protection [152-155]. This limited breadth 
of protection can be explained by the selective pressure exerted by the immune system, 
which gives rise to new strain variants that can evade previously elicited antibodies; this 
process is called antigenic drift and will be covered in detail later. 
HA Stalk Antibodies 
The HA stalk is immunosubdominant to the HA head; antibody responses against 
this domain typically constitute a small fraction of the overall antibody response against 
influenza in humans [148]. The exact cause of the HA stalk domain’s 
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immunosubdominance has not yet been determined. One proposed hypothesis is based 
on the concept of steric hindrance [156], or limited access to HA stalk epitopes. Shielding 
of the HA stalk domain by the HA head or other surface proteins is plausible, as the IAV 
membrane is tightly packed with the surface glycoproteins HA and NA, with an average 
packing density of about 375 glycoproteins per virion, resulting in an average of 11 nm 
spacing between each glycoprotein spike [157]. It has also been postulated that the HA 
stalk domain may be inaccessible due to its proximity to the viral membrane, based on the 
observed bias of the hydrophobic VH1-69 immunoglobulin gene usage within humans to 
encode for HA stalk-reactive antibodies [158-161]. However, recombinant HA vaccines 
have failed to elicit robust HA stalk antibody titers [162] and cryoelectron tomography has 
demonstrated that the majority of HA proteins on influenza virions are available to stalk-
specific antibodies [163], suggesting that steric hindrance is not an issue. An alternative 
hypothesis proposes B cells specific for HA stalk epitopes are under negative selection, 
based on the observation that HA stalk antibodies can be polyreactive [156], which may 
contribute to HA stalk antibody immunosubdominance.  
Despite the issue of immunosubdominance, HA stalk antibodies are often broadly 
cross-reactive, due to the high conservation of the stalk domain within and across 
influenza subtypes, and they are able to mediate protection through a variety of 
mechanisms. Monoclonal antibodies (mAbs) have been isolated from humans that bind a 
conformationally-dependent epitope that spans the HA1-HA2 interface, thus locking the 
HA into its pre-fusion form to block pH-induced viral-endosomal membrane fusion [58, 
147, 148, 164, 165], to inhibit viral egress [164] or to prevent HA0 maturation [165]. A new 
mechanism of HA stalk antibody-mediated protection was recently described, whereby 
steric hindrance from bound HA stalk antibodies prevent the enzymatic activity of the viral 
membrane protein NA [166].  Additionally, many broadly neutralizing HA stalk antibodies 
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mediate protective mechanisms by coupling antigen binding with Fc-mediated effector 
function [167, 168]. Fcγ receptors (FcγRs) are a major regulatory component of the 
immune system that couples innate and adaptive immunity. Many immune cells express 
both activating and inhibitory FcγRs; the paired expression and signaling of these 
receptors is required for establishing a balanced immune response [169]. Additionally, 
FcγRs have varying affinity for individual antibody isotypes, rendering an additional layer 
of regulatory control over Fc-mediated effector functions [170, 171].  
HA stalk antibodies have demonstrated the ability to induce all of the Fc-receptor 
mediated functions that have long been known to play a role during influenza infection and 
vaccination [172]: antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent 
cellular phagocytosis (ADCP), and antibody-dependent complement-mediated lysis 
(ADCL). ADCC is induced when the Fc domain of IgG1 or IgG3 antibodies bind the HA 
stalk, presented on the surface of infected cells, and simultaneously engage the FcγRIIIA 
(CD16) found on NK cells, monocytes/macrophages, and neutrophils [172]. CD16 signals 
through ITAM to activate downstream calcium-dependent signaling pathways that 
culminate in the release of granzyme B and perforin, facilitating DNA fragmentation and 
apoptosis of the infected target cell [131]. ADCP is induced by HA stalk antibodies 
opsonizing the surface of influenza-infected cells or by forming immune complexes. The 
Fc-domain of these antibodies then interact with innate phagocytic immune cells bearing 
either FcγRIIb (CD32) or FcγRI (CD64), predominantly engaged by IgG1 or IgG3, or FcαRI 
(CD89), engaged by IgA, inducing uptake of the infected target cell or immune complex 
[131, 173, 174]. ADCL is initiated when the Fc domain of antibodies (IgG1 or IgG3) bound 
to the HA stalk, expressed on the cell surface of infected cells, recruits the C1q protein 
[175-178]. Binding of C1q triggers the complement cascade and formation of the 
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membrane attack complex at the surface of the infected cell, inducing cell lysis and a 
proinflammatory environment [131]. 
It is important to note that HA stalk antibodies should not be categorized as those 
that “neutralize” or those that “mediate Fc effector functions”; rather, many HA stalk 
antibodies seem to have a number of functions (both direct and indirect) available to them, 
given their specific isotype and ability to engage Fc receptors [179, 180]. Some of the 
factors that have been shown to impact Fc receptor engagement are concentration, 
isotype, binding specificity, and Fc glycosylation [172]. Additionally, recent work suggests 
that HA stalk antibodies require the HA to be bound to sialic acid for optimal activation of 
effector cells through Fc-receptor interactions [181]. 
 
Section 1.4 - Unique challenges for influenza immunity  
For many viruses, elicitation of a neutralizing antibody response will confer life-
long immunity. However, influenza viruses and the host immune response to IAV 
infection/vaccination present some unique challenges that prevent the development of 
complete immunity.  
Antigenic drift  
The error-prone RNA polymerase of influenza virus plays an essential role in 
facilitating antigenic drift, whereby population immunity to IAVs drives the process of 
selecting antigenic variants in HA and NA that contain substitutions which abrogate 
binding of pre-existing antibodies [5, 182, 183]. Due to the selective advantage of immune-
escape, drifted viruses dominate circulation [184-186] and the amino acid substitutions 
become fixed in circulating influenza strains. Antigenic drift facilitates continuous 
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circulation of seasonal influenza virus strains within the human population, undermining 
seasonal vaccine efficacy and causing considerable morbidity and mortality [187].  
Why do we have effective vaccines for other RNA viruses, but not for influenza 
viruses? Similar to influenza viruses, measles virus is also an RNA virus with an error-
prone RNA polymerase and subsequently high mutation rate. However, unlike influenza 
viruses, infection with measles viruses protects against reinfection, and vaccination with 
either the combined MMR (measles, mumps, rubella) or the stand-alone measles vaccine 
provides 99.7% of people with complete, lasting immunity to measles infection [188]. 
Additionally, the measles vaccine has remained highly effective against currently 
circulating measles viruses, indicating that viral escape from vaccine-induced immunity 
has not occurred [189]. While the RNA polymerase of measles virus is also error-prone, 
the surface proteins of measles (the target of human immunity) are highly intolerant of 
mutations [190]. Therefore, while mutations are likely introduced into the measles genome 
at a rate similar to that of influenza, the inelasticity of the surface glycoproteins may 
contribute to the observed lack of antigenic variation, as antigenic variants are unable to 
replicate well [190]. The result is a virus that is restricted to its original genetic identity, 
making a stable target for antibodies elicited from a single round of vaccinations [190]. In 
contrast, the surface proteins of influenza virus are exquisitely tolerant of mutations 
introduced by the error-prone RNA polymerase [191]; this allows for a single mutational 
“parent strain” to proliferate and their progeny to acquire new and different mutations, 
ultimately resulting in the phylogenetic diversity of influenza viruses circulating today.  
It is important to note that not all genetic changes in HA affect antigenicity. Amino 
acid substitutions can also be selected to fine-tune HA function, to compensate for other 
substitutions to maintain viral fitness, or simply be the result of the error-prone polymerase 
in regions of the protein that are not antigenically important. Determining the functional 
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consequences for individual substitutions is fundamental to understanding how influenza 
viruses evade host immune responses and to designing better vaccines. I will be covering 
this in greater detail in Chapters 3 and 4. 
Antigenic shift 
Antigenic shift occurs when a novel influenza viral strain enters a human 
population for the first time. Circulating influenza viruses are incredibly diverse and are a 
significant source of zoonotic infection. The diversity is due in no small part to the 
segmented genome of influenza viruses, which facilitates recombination between strains. 
Cells that are co-infected by viruses of different subtypes can swap genomic segments, 
generating new viral variants that can have altered virulence and/or antigenic properties 
[192]. By swapping genetic segments, a novel influenza virus can arise that contains 
highly pathogenic attributes and the transmissibility from other viruses that previously 
circulated in humans [192]. Importantly, viral reassortment can result in zoonotic spillover 
events, allowing viral variants to jump from circulation in one species into another species 
[193]. 
The influenza pandemics of 1957 (H2N2), 1968 (H3N2), and 2009 (H1N1) were 
the result of reassortment events between avian, swine, and human influenza strains [194-
197]. The burden of zoonotic spillover events, with their potential to cause pandemics, has 
attracted global attention since it was identified that influenza A viruses of both avian and 
swine origin can be directly transmitted to humans. This direct transmission was especially 
notable with the H5N1 lineage (A/Goose/Guangdong/96) that infected 860 people and 
caused 454 deaths through December 2017 [198]. Thus far, sustained human-to-human 
transmission of H5N1, or H7N9 (a group 2 influenza virus that has caused significant 
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mortality rates in isolated outbreaks) [199], have not been detected, but represent potential 
pandemic strains that are poised to jump directly into human circulation.  
Reverse zoonosis (human to animal transmission) also poses a significant 
pandemic threat. Pigs might be an important “mixing vessel” for the emergence of 
potentially pandemic reassortment viral variants due to their susceptibility to most 
influenza A strains and because their respiratory tract contains the receptors for both avian 
and mammalian influenza stains (α2,3- and α2,6-linked sialic acid, respectively) [193]. 
Since 2009, repeated reverse zoonosis of the human pH1N1 strain into pigs has 
contributed to the expansion of the genetic diversity of swine influenza A viruses [200]. 
Potential pandemic strains have emerged from these reassortment events, such as the 
H3N2v swine IAV that infected more than 300 humans in the United States during 2011-
2013 [201]. 
The continuous reassortment and spillover events make it increasingly difficult to 
predict what influenza strains may cause the next influenza pandemic. Determining what 
molecular evolutionary changes allow certain influenza strains to jump between host 
species remains an important question in influenza research and is crucial for the 
development of prevention measures. 
Immune imprinting 
Influenza immunity has an additional layer of complexity that has been observed 
since the 1950s: while antibodies elicited by a primary influenza virus exposure are highly 
strain-specific, antibodies elicited by an antigenically distinct, secondary influenza 
exposure tend to be highly cross-reactive with the first strain [202-204], but may be poorly 
reactive to the second strain [205, 206]. This phenomenon was originally described as 
‘original antigenic sin’ by Thomas Francis, Jr, referring to the notion that an individual’s 
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immune system will bear the “sin” of their very first childhood exposure to influenza, and 
that this will influence the antibody response to all subsequent influenza exposures [204]. 
However, this phenomenon should not be misinterpreted as a strictly deleterious 
consequence of sequential influenza virus exposures. Indeed, the contemporary phrasing 
of ‘antigenic seniority’ [207] or ‘immune imprinting‘ [208] may more accurately represent 
the immune system’s ability to develop high-affinity, cross-reactive antibody responses 
over time through the sequential exposure of antigenically distinct viral strains. 
While the exact mechanisms behind ‘original antigenic sin’ have not been fully 
elucidated, the concept refers to the propensity of the immune system to preferentially 
recall memory B cells that target antigenic epitopes conserved between primary and 
subsequent influenza virus exposures [209, 210]. Multiple mechanisms may influence this 
preferential recall of memory B cells. First, the availability of antigen for strain-specific 
naïve B cells is likely diminished due to previously established immune responses in the 
form of broadly neutralizing antibodies, effector functions induced by cross-reactive 
antibodies (ADCC, ADCP, etc), and cytotoxic T cells [211, 212]. The second contributing 
mechanism is a competition for antigen access between naïve B cells reactive to novel 
epitopes of secondary influenza strains and memory B cells that have higher antigen 
avidity and a lower threshold of activation [213]. The higher avidity of memory B cells 
confers a competitive advantage over naïve B cells for access to antigen and signaling 
from T follicular helper (TFH) cells, increasing the likelihood of a memory response over a 
de novo response. When memory B cells are recalled, they re-enter a period of clonal 
expansion and somatic hypermutation to generate a high affinity antibody response 
against the new viral strain [214], resulting in an immune repertoire that gradually 
increases its concentration of highly cross-reactive antibodies that target conserved, 
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subdominant epitopes as the host ages and is sequentially exposed to antigenically 
distinct viral strains [156, 215]. 
Immune imprinting was evident during the 2009 H1N1 pandemic. The pH1N1 HA 
amino acid sequence was 27.2% different from the human H1N1 HA circulating in 2008 
[216]. However, the HA stalk remained relatively well conserved, resulting in the 
preferential boosting of HA stalk antibodies in many adults [217-219]. Other studies 
identified individuals with immune responses focused on a rare HA head epitope that was 
conserved from the seasonal H1N1 (sH1N1) strain that had circulated during their 
childhood [220-223]. Importantly, the ability to skew antibody responses towards epitopes 
conserved between sH1N1 and pH1N1 strains were recapitulated in ferrets after 
sequential infection with a 1991 sH1N1 virus and the 2009 pH1N1 virus [221]. Taken 
together, these studies demonstrate that the host’s year of birth influences the antibody 
response for a given influenza infection.  
It has become increasingly clear that individuals recall memory B cells that target 
HA epitopes conserved amongst subtypes within both group 1 and group 2 influenza A 
viruses [224-226], and that immune imprinting is important for pandemic virus 
susceptibility. This is consistent with an epidemiological study from Gostic et al, who 
demonstrated a correlation between the probability of first influenza exposure to either a 
group 1 or group 2 HA (based on year of birth and circulating seasonal influenza strains) 
and susceptibility to avian H5N1 and H7N9 influenza strains [208]. They found that 
individuals primed with a group 1 HA appeared to be protected from H5N1 (group1 HA, 
Figure 1.1) but susceptible to H7N9 (group 2 HA, Figure 1.1). Conversely, individuals 
primed with a group 2 HA appeared to be protected from H7N9, but susceptible to H5N1. 
All individuals were likely exposed to both group 1 and group 2 HAs throughout their life, 
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given normal seasonal circulation, suggesting that the first infection that an individual 
encounters is the most important for establishing long-lived immune memory. 
The apparent heterosubtypic protection observed in the Gostic study is likely 
mediated by HA stalk antibodies. The majority of broadly neutralizing antibodies target 
epitopes in the HA stalk domain as this domain is highly conserved across influenza 
strains [147, 148, 227]. Broadly neutralizing HA stalk antibody responses are induced 
following natural influenza infection [218, 228, 229] and can be boosted through 
vaccination by HAs with antigenically distinct head domains [230-236]. The ability to 
induce a neutralizing, cross-reactive antibody response is currently being explored as a 
tool to improve seasonal influenza vaccine efficacy and to mitigate the impact of a future 
influenza pandemic, as will be described below.  
 
Section 1.5 - Correlates of protection 
The CDC estimates the effectiveness of seasonal influenza vaccines through 
several surveillance networks that perform observational studies to assess how well the 
influenza vaccine is working that year to prevent infections, medical visits, and 
hospitalizations [4]. The effectiveness of the vaccine is determined by comparing the 
frequency of vaccinated versus unvaccinated individuals with PCR-confirmed influenza 
infections [4]. The identification of a true correlate of protection – a test that can accurately 
predict the effectiveness of a vaccine – is one of the ‘holy grails’ of vaccine development 
[237, 238]. Typically, serological assays are performed to measure surrogate markers for 
immunity and protection [239]. 
For influenza, measurement of HA head antibodies has historically been the gold 
standard for determining seroconversion and immunogenicity in vaccine studies. 
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Hemagglutination inhibition (HAI) assays measure the presence of antibodies in the serum 
to prevent agglutination of red blood cells, mediated by HA binding to sialic acid that 
decorates the surface of the red blood cells. The HAI antibody titers are then used as a 
proxy for the ability of antibodies to inhibit viral receptor binding [240, 241], with an HAI 
titer of >1:40 considered a surrogate marker for approximately 50% protection against 
influenza infection [241, 242]. HAI titers are widely used as a surrogate of protection and 
have been included in vaccine licensure requirements by several regulatory authorities 
[243, 244], resulting in vaccine development that focused on elicitation of high HAI titers. 
Unfortunately, this threshold is far less predictive of protection in children and the elderly 
[245, 246], and does not provide any information about antibodies that may neutralize 
through mechanisms other than inhibition of receptor binding.  
In an effort to address this shortcoming, microneutralization (MN) assays have 
been used in recent years to measure the ability of antibodies to inhibit viral infection and 
replication in cell culture [247]. This technique detects functional antibodies that directly 
neutralize the ability of a virus to enter a host cell or to replicate/spread, and therefore 
detects antibodies against all viral proteins [248]. However, no correlates of protection 
have yet been defined for MN titers, making it difficult to compare to HAI assays and 
assessments for vaccine effectiveness [249]. Additionally, the complexity of this assay 
increases the risk of inter-laboratory variability, though the inclusion of antibody standards 
has increased reproducibility [250]. 
In addition to traditional immunological techniques, the enzyme-linked 
immunosorbent assay (ELISA) is a commonly used assay to detect anti-influenza 
antibodies [251]. The advantages of this technique are that it is suitable for large-scale 
serological investigations, is reproducible with readily available standardized reagents, 
and can be used to detect protein-specific antibody subsets (through the use of purified, 
22 
 
recombinant proteins) and/or individual antibody isotypes [239, 252-255]. The primary 
disadvantage of an ELISA is that it only measures the prevalence of antibodies, regardless 
of their functionality. This caveat likely contributes to the lack of an ELISA-based correlate 
of protection being established yet. 
However, the human immune response is a highly interconnected and dynamic 
system that does not operate in a vacuum, and important subsets of neutralizing 
antibodies may be missed by these traditional immunological techniques. T cell-mediated 
immunity and effector functions mediated by Fc-receptor interactions with antibodies are 
important contributors to protection and should be evaluated accordingly. As I will discuss 
in detail later, vaccines are currently being developed to elicit broadly neutralizing HA 
stalk-specific antibodies with direct and indirect functionality that may not be detected by 
these traditional assays. It is therefore imperative that assays be developed to detect 
these unique antibody subsets and correlates of protection using these assays be 
established.  
 
Section 1.6 - Seasonal influenza vaccines 
IAV was first isolated from the nasal secretions of infected human patients in 1932-
33 [256], followed quickly by the discovery that influenza A viruses could be grown in the 
allantoic fluid of embryonated chicken eggs in 1935 [257]. Over the next five years the 
process for developing influenza vaccines was elucidated - from the immunogenicity of 
formalin-inactivated virus to the purification of viruses harvested from embryonated 




Influenza vaccines have been repeatedly transformed over the years to 
accommodate the continual advancement in the fields of influenza virology and human 
immunology. What began as an inactivated, monovalent preparation of only influenza A 
in the early 1940’s has become a trivalent or quadrivalent preparation containing antigens 
from one H1N1 strain and one H3N2 strain, combined with either one or two strains of 
influenza B virus [259]. Generation of the vaccine components has also diversified – some 
vaccines contain only a recombinant HA protein grown in insect cells and others contain 
influenza virus grown in mammalian cell culture or embryonated chicken eggs; 
additionally, whole virus preparations can be either chemically inactivated or be live-
attenuated [260, 261]. However, the vast majority of seasonal influenza vaccines are still 
produced by growing the virus in embryonated chicken eggs, chemically inactivating the 
virus, then purification – the same procedure that was originally developed in the 1940s 
[259]. 
The advent of global surveillance of circulating influenza strains has greatly 
influenced the composition of antigens used in influenza vaccines. The first influenza 
surveillance system, Global Influenza Surveillance and Response System (GISRIS), was 
established by the World Health Organization in 1952 to monitor antigenic drift of 
circulating viruses around the world [262]. The newly established surveillance system 
provided an innovative tool that enabled the composition of influenza vaccines to be based 
on the epidemiology of circulating influenza viruses from the previous season.  
The strains included in the seasonal vaccine must be updated frequently to adjust 
for the antigenic substitutions that confer escape from antibodies boosted by vaccination. 
Through the GISRIS centers, circulating influenza strains are isolated from infected 
individuals, sequenced, and antigenically characterized. To determine whether antigenic 
changes have occurred in circulating strains that confer escape from vaccine-induced 
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immunity, ferrets are infected with the vaccine strain [263]. The ferret antiserum, and in 
recent years human serum [264], is tested by various serological assays to screen for 
antigenic differences between previous vaccine strains and circulating strains. If the tested 
sera demonstrates poor inhibition of hemagglutination, the vaccine strain is generally 
updated [263]. To update the vaccine strains, the HA and NA genes from some of the viral 
isolates are incorporated into high-growth reassortant strains using the six internal gene 
segments of the culture-adapted virus A/Puerto Rico/8/1934 (PR8). From these high-
growth reassortant strains, candidate vaccine viruses (CVVs) are selected and are 
recommended for use as seed strains to influenza vaccine manufacturers.  
Our current system for seasonal vaccine strain selection and production provides 
ample opportunity for antigenic mismatch to occur between the selected vaccine strain 
and the circulating strain. The vast majority (~82%) of influenza vaccines were produced 
in chicken eggs for the 2019-2020 influenza season [265]. Influenza viruses must adapt 
for growth in chicken eggs to accommodate the α2,3-linked sialic acid present on avian 
cells, often resulting in amino acid substitutions at or near the receptor binding sites of HA 
[266]. Human influenza viruses acquire HA substitutions that improve binding to α2,3-
linked sialic acid when grown in chicken eggs, but these substitutions have the potential 
to cause an antigenic mismatch between the vaccine and circulating strain [267, 268].  
The timeline required for producing enough influenza vaccine doses is another 
contributing factor towards the occurrence of antigenic mismatch. One embryonated 
chicken egg produces enough virus for approximately one vaccine dose; with 
approximately 162 million doses of vaccine projected to be produced and distributed within 
the United States for the 2019-2020 influenza season alone, this requires a demanding 
production schedule [265]. To meet this production deadline, vaccine manufacturers must 
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begin production in the Northern Hemisphere immediately after vaccine strain selection is 
announced in February, even though vaccine doses aren’t distributed until September or 
October. During the 8-9 month interim between strain selection and vaccine distribution, 
antigenically distinct strains containing novel substitutions can emerge, resulting in an 
antigenic mismatch between the vaccine and circulating influenza strains [269]. 
When antigenically drifted strains circulate during an influenza season, vaccine 
efficacy can be greatly reduced, as evidenced by the 2014-2015 influenza season when 
there was an antigenic mismatch between the vaccine and circulating influenza strains 
[270]. The population vulnerability that is imposed by our current vaccine production 
system is especially evident when an influenza pandemic occurs. During the 2009 H1N1 
pandemic the vaccine containing the new pandemic strain arrived too late to prevent the 
majority of infections that occurred [271]. Indeed, it was our vulnerability during the 2009 
H1N1 pandemic that imbued a sense of urgency in the pursuit of a better influenza vaccine 
- a vaccine that not only protects against antigenically drifted seasonal strains, but also 
against future pandemic strains. 
 
Section 1.7 - Pursuit of a universal influenza vaccine 
A universal influenza vaccine would be one that confers protection against all 
HA/NA subtypes of influenza A viruses, independent of antigenic drift. To achieve this, a 
vaccine must be designed that redirects the human immune response towards a highly 
conserved viral target that can elicit broadly neutralizing antibodies. Several targets for 
universal influenza vaccines are currently being explored, including the HA stalk domain 
[272-275], NA [276], the ectodomain of the M2 ion channel [277], as well as the internal 
proteins NP and M1 [278, 279].  
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The HA stalk domain has become one of the more promising targets in the 
development of a universal influenza vaccine, with two different platforms currently in 
clinical trials (discussed below). The HA stalk domain is an appealing target because it is 
relatively intolerant to change [191, 280-282] and is highly conserved across influenza 
strains, with some central residues being 100% identical across all subtypes [147, 148, 
227]. Three protective epitopes have been identified with varying levels of cross-reactivity 
between influenza A strains (Figure 1.3). Epitope 1 is located on the A a-helix of HA2. 
Antibodies that target this domain confer the broadest protection, as this epitope is 
conserved across Influenza A groups 1 and 2 [147, 148, 217, 283, 284]; however, 
antibodies that target this epitope must have unique characteristics to accommodate the 
glycan modifications that can obscure this epitope across influenza strains [283]. Epitopes 
2 and 3 are conserved between group 2 influenza A subtypes; epitope 2 spans the upper 
portion of the long CD  alpha helix in HA2 [285] and epitope 3 contains the fusion peptide 
and helix-capping loops at the base of the HA stalk [286]. Induction of a robust antibody 
response against these conserved epitopes, particularly epitope 1, would confer broader 
and more durable protection against influenza infection by circumventing our current 
reliance on epitopes subject to antigenic drift. 
Humans have an extensive immune history with influenza, both through 
vaccination and natural infection. The resulting memory B cell repertoire is the primary 
source of HA stalk-specific antibodies, based on the extensive mutation load and binding 
affinity found within this compartment [156, 217, 218]. Additionally, the onset of the 2009 
H1N1 pandemic revealed that many individuals did not seroconvert for HA head 
antibodies post-infection or post-vaccination [218, 219]; rather, memory B cells for 
conserved epitopes within the HA stalk domain were preferentially recalled, inducing a 
more broadly neutralizing antibody response [218, 287]. Therefore, development of a 
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universal influenza vaccine that is designed to capitalize on the pre-existing memory B 
cells against the HA stalk domain would seem a reasonable path forward. However, it is 
difficult to elicit HA stalk-specific responses from traditional vaccine approaches due to the 
immunodominance of the HA head domain [222]. To address this difficulty, HA stalk-





Chimeric HA vaccine 
One approach is based on chimeric HAs (cHAs) composed of the H1, H3, or 
influenza B HA stalk domains combined with the HA heads of ‘exotic’ influenza subtypes 
that have not circulated in humans previously, usually from an avian influenza strain [288-
290]. The strategy is to sequentially vaccinate, using cHAs containing different head 
domains for each vaccination. In this way, a de novo response is generated against the 
exotic HA head, while a memory B cell response is boosted against the conserved HA 
stalk, with each subsequent vaccination. This cHA vaccine approach has been tested in 
both mouse and ferret models using the H1 stalk cHA (containing first an H5 head, 
followed by an H8 head), and was found to protect from challenge with diverse influenza 
viruses [291-294].  
The c5/H1-c8/H1 prime-boost vaccine regimen has recently completed a phase I 
clinical trial in a collaboration between Icahn School of Medicine Mount Sinai and 
GlaxoSmithKline (GSK) to test the immunogenicity and safety of either a live-attenuated 
or inactivated cHA sequential vaccine with and without the GSK adjuvant, AS03 
(clinicaltrials.gov, NCT03300050). According to the interim report [272], the primary 
vaccine (adjuvanted c5/H1 inactivated virus) induced a robust IgG response against the 
H1 HA stalk, reaching a 7-fold increase above baseline titers by day 29 post-vaccination, 
whereas the live-attenuated vaccine did not induce a strong anti-stalk response. Following 
the booster vaccination (c8/H1), all vaccine regimens induced detectable H1 HA stalk IgG 
responses that were cross-reactive; however, a strong memory B cell response was only 
induced by the inactivated/adjuvanted prime vaccination. At the time of this writing, final 
results from this trial have not been published. 
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Headless HA stalk nanoparticle vaccine 
The second strategy to elicit HA stalk-specific antibody responses comes in the 
form of a nanoparticle coated in ‘headless’ HA stalk constructs. While the development of 
a stable, conformationally intact ‘headless’ HA stalk is challenging, constructs have been 
successfully generated for both group 1 [273, 275] and group 2 [274] influenza A viruses. 
This strategy has the advantage of removing the immunodominant head altogether, 
allowing for an exclusively HA stalk-focused immune response to occur. Additionally, a 
ferritin nanoparticle is used as the vaccine delivery platform, which allows multiple HA 
stalk proteins to be displayed on its surface, mimicking the natural organization of HA on 
an influenza virion. The H1 HA ‘headless’ stalk nanoparticle has demonstrated 
heterosubtypic protection in both mouse and ferret models [273], and a clinical trial 
(NCT03186781), testing a full-length H1 HA on the ferritin nanoparticle, demonstrated the 
safety and tolerability of the nanoparticle platform in humans. The group 1 (H1) headless 
HA stalk nanoparticle vaccine is currently in a clinical trial (NCT03814720) through the 
Vaccine Research Center at the National Institute of Allergy and Infectious Diseases 
(NIAID), though at the time of this writing the results have not yet been published. 
Section 1.8 - Experimental questions 
To achieve the goal of developing a universal influenza vaccine, we must identify 
a viral antigen that is not only targeted by potent antibodies but is also conserved across 
all HA subtypes and largely intolerant to antigenic drift. The HA stalk domain is largely 
conserved between the HA subtypes, and antibodies against this domain have provided 
heterosubtypic protection in numerous animal models. However, important questions 
need to be answered before determining if an HA stalk-based universal influenza vaccine 
will provide broad protection against seasonal and pandemic influenza strains. Are H1 HA 
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stalk antibodies associated with protection against sH1N1 infection and/or severe disease 
in humans? Can we establish correlates of HA stalk antibody-mediated protection? What 
easily-standardized and reproducible assays should be developed to accurately predict 
vaccine efficacy using a correlate of protection that functions through numerous 
mechanisms of protection? Is the H1 HA stalk domain susceptible to antigenic drift, or is 
it a stable target for long-term protection?  
In Chapter 2, we utilize a human serological cohort to determine if H1 HA stalk 
antibodies are associated with protection against H1N1 influenza infection and disease, 
and to characterize this antibody subset. We demonstrate that HA head antibody titers are 
independently associated with protection against influenza infection and confer potent 
protection in vivo against viral challenge. We also show that HA stalk antibody titers are 
associated with protection against human influenza infection, and that HA stalk antibodies 
provided moderate protection in vivo against viral challenge of mice. Additionally, we 
characterized the isotype composition and probed the functional features of the H1 HA 
stalk antibody subset in human sera. This study demonstrates for the first time that human 
HA stalk antibodies in polyclonal serum are associated with protection in adults and can 
protect against H1N1 severe influenza disease in mice in the absence of HA head 
antibodies. 
In Chapter 3 we identify six amino acid substitutions in the H1 HA stalk domain 
that have become fixed in circulating viral populations since 2009. Using a human 
serological cohort, we demonstrate these amino acid substitutions have not decreased 
the binding or affinity of antibodies in polyclonal sera in a biologically relevant manner, 
indicating antigenic drift has not occurred in the H1 HA stalk domain for the entirety of this 
subtype’s circulating history. This observation suggests that while the HA stalk is not 
completely intolerant to change, these changes do not appear to alter the antigenicity of 
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this protein. This study illustrates the durability of the HA stalk domain as a target for a 
universal influenza vaccine approach. 
Finally, in Chapter 4, I will discuss the implications of our findings for the pursuit of 
an HA stalk-based universal influenza vaccine. I will also address how these results can 
launch new investigations into the functionality and applicability of HA stalk antibodies for 
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Section 2.1 - Abstract 
Seasonal influenza viruses are a major cause of human disease worldwide. Most 
neutralizing antibodies (Abs) elicited by influenza viruses target the head domain of the 
hemagglutinin (HA) protein. Anti-HA head antibodies can be highly potent, but they have 
limited breadth since the HA head is variable. There is great interest in developing new 
universal immunization strategies that elicit broadly neutralizing antibodies against 
conserved regions of HA, such as the stalk domain. Although HA stalk antibodies can 
provide protection in animal models, it is unknown if they are present at sufficient levels in 
humans to provide protection against naturally acquired influenza virus infections. Here, 
we quantified H1N1 HA head- and stalk-specific antibodies in 179 adults hospitalized 
during the 2015–2016 influenza virus season. We found that HA head antibodies, as 
measured by hemagglutinin inhibition (HAI) assays, were associated with protection 
against naturally acquired H1N1 infection. HA stalk-specific serum total IgG titers were 
also associated with protection, but this association was attenuated and not statistically 
significant after adjustment for HA head-specific antibody titers. We found slightly higher 
titers of HA stalk-specific IgG1 and IgA antibodies in sera from uninfected participants than 
in sera from infected participants; however, we found no difference in serum in 
vitro antibody-dependent cellular cytotoxicity activity. In passive transfer experiments, 
sera from participants with high HAI activity efficiently protected mice, while sera with low 
HAI activity protected mice to a lower extent. Our data suggest that HA head antibodies 





Section 2.2 - Introduction 
Seasonal influenza viruses cause annual epidemics worldwide. Although seasonal 
influenza vaccines usually provide moderate protection against circulating strains, vaccine 
effectiveness can be low when there are antigenic mismatches between vaccine strains 
and circulating strains [295, 296]. Additionally, rare yet unpredictable influenza pandemics 
occur when novel influenza virus strains cross the species barrier and transmit in the 
human population [2]. 
Antibody-mediated immunity is important for protecting against influenza virus 
infections [297]. The viral membrane protein, hemagglutinin (HA), is the target for most 
anti-influenza virus neutralizing antibodies [133, 298-301]. Most neutralizing HA 
antibodies target the HA globular head domain and block virus attachment to sialic acid, 
the cellular receptor for influenza viruses. However, since the HA head is highly variable, 
HA head antibodies generally exhibit poor cross-reactivity against antigenically drifted viral 
strains [302]. Unlike the head domain, the stalk domain of HA is highly conserved between 
different influenza virus strains. Antibodies that target the HA stalk domain can prevent 
viral replication by inhibiting the pH-induced conformational changes of HA that are 
required for viral entry into the cell [165]. Many HA stalk-specific antibodies also protect 
by blocking HA maturation [165], inhibiting viral egress [164], or mediating Ab-dependent 
cellular cytotoxicity (ADCC) [168]. Although HA stalk antibodies are typically subdominant 
and are not thought to be as efficient as HA head Abs, HA stalk antibodies can inhibit 
diverse influenza strains in vitro [148, 158, 284, 286]. 
Conventional influenza vaccines effectively elicit HA head-reactive antibodies but 
not HA stalk antibodies [303]. As a result, influenza vaccine effectiveness is dependent on 
the similarity of the HA head of circulating influenza virus strains and the HA head of 
vaccine strains [304]. Antigenic mismatch between influenza vaccine strains and 
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circulating viral strains have been especially problematic during recent years [223, 267]. 
To circumvent the potential for antigenic mismatch, as well as to prepare against new 
pandemic viral strains, there is great interest in developing new universal immunization 
strategies that elicit broadly reactive antibodies against conserved regions of HA, such as 
the stalk domain [286, 305]. 
HA stalk antibodies protect animals from group 1 and group 2 influenza A virus 
infections [158, 218, 285, 286, 306-310]. For example, human anti-HA stalk monoclonal 
antibodies (mAbs) protect mice from lethal pH1N1 infection following prophylactic or 
therapeutic passive transfers [218, 310] as well as against H5N1 [158, 306, 310] or H7N9 
lethal dose challenge [309]. Both the prophylactic passive transfer of a human anti-HA 
stalk mAb or the elicitation of HA stalk-specific antibodies by chimeric HA vaccination 
decreases viral loads in ferrets following pH1N1 infection [307]. Additionally, passive 
transfer of human sera from H5N1 vaccinees protects mice from lethal pH1N1 infection 
[308], and this protection is likely mediated by HA stalk Abs. Passive transfer of broadly 
neutralizing HA stalk-specific mAbs against group 2 influenza A viruses also protects mice 
against heterosubtypic H3 viruses [285] and heterologous H3 and H7 viruses [286]. 
Vaccine strategies designed to elicit HA stalk antibodies in humans are currently being 
pursued [273, 311, 312]. These strategies include sequential immunizations with chimeric 
HAs [288, 304], immunization with headless HA antigens [159, 273, 275], and 
immunizations with mRNA-based vaccines expressing HA [312]. 
Despite the recent interest in developing new HA stalk-based vaccines, the amount 
of HA stalk antibodies required to protect humans from influenza virus infections and 
influenza-related disease has not been established. A recent human pH1N1 challenge 
study demonstrated that HA stalk antibody titers are associated with reduced viral 
shedding but are not independently associated with protection against influenza infection 
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[313]. While human influenza virus challenge studies are valuable, they have some 
limitations. For example, high doses of virus are used in these studies [314, 315], large 
numbers of individuals are typically prescreened for certain immunological attributes prior 
to entering these studies [316], and the pathogenesis of infection differs from that of a 
natural infection, including key sites of viral replication [315, 317]. Serological studies of 
individuals who naturally acquire influenza virus infections can also be used to identify 
specific types of antibodies that are associated with protection. Here, we present a 
serological study to determine if serum HA head and stalk antibodies are associated with 
protection against naturally acquired H1N1 infection. 
 
Section 2.3 - Results 
Assessment of HA head and stalk antibody association with protection against 
H1N1 infection 
We analyzed sera collected from 179 participants enrolled in a hospital-based 
study during the 2015–2016 influenza season (Table 2.1). Adults hospitalized at the 
University of Michigan Hospital (Ann Arbor, MI, USA) or Henry Ford Hospital (Detroit, MI, 
USA) were enrolled according to a case definition of within ≤10 days of acute respiratory 
illness onset and subsequently tested for influenza by reverse transcription-PCR (RT-
PCR). Serum specimens collected at hospital admission were obtained for estimation of 
preinfection/early infection antibodies; 58% of specimens included in this analysis were 
collected within 3 days of illness onset [318]. We analyzed serum samples from 62 
hospitalized individuals that had PCR-confirmed H1N1 influenza virus infections. Serum 
samples from 117 controls were selected from hospitalized individuals that had other 
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respiratory diseases not caused by an influenza virus infection, matching by age category 
(18 to 49 years, 50 to 64 years, and ≥65 years) and influenza vaccination status. 
We quantified serum titers of HA head-specific antibodies against the predominant 
2015–2016 H1N1 strain using hemagglutination inhibition (HAI) assays (Figure 2.1). HAI 
assays detect HA head-specific antibodies that prevent influenza virus-mediated cross-
linking of red blood cells [240, 241]. We found that HAI titers were associated with 
protection against H1N1 infection in logistic regression models (Table 2.2). We observed 
a 23.4% reduction in H1N1 infection risk with every 2-fold increase in HAI titer. Previous 
studies reported that a 1:40 HAI titer is associated with 50% protection from experimental 
human influenza infections [242]. Consistent with this, over 21% of non-H1N1-infected 
cases possessed an HAI titer of >40, while only ∼3% of H1N1-infected cases possessed 
an HAI titer of >40. 
We next quantified relative titers of H1 stalk IgG antibodies using enzyme-linked 
immunosorbent assays (ELISAs) coated with headless H1 proteins (Figure 2.1). Similar 
to HAI titers, we found that H1 stalk titers were associated with protection against H1N1 
infection in logistic regression models (Table 2.2). We observed a 14.2% reduction in 
H1N1 infection risk with every 2-fold increase in H1 stalk titer. Whereas HAI titers of >40 
were sharply associated with protection (Figure 2.1), there was no clear HA stalk IgG titer 
cutoff that was associated with protection in our study (Figure 2.1)Samples with the 
highest HA stalk IgG titers were interspersed among the uninfected and infected groups 
(Figure 2.1) 
Although both HAI titers and HA stalk IgG titers were associated with H1N1 
protection in unadjusted models (Table 2.2), only HAI titers remained statistically 
associated with protection in adjusted models (Table 2.2). HA stalk IgG-associated 
protection lost significance when adjusting for HAI titers; however, the overall reduction in 
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odds of infection for each 2-fold increase in titer remained roughly the same between the 
unadjusted and adjusted models for both HAI (23.4% to 20.7%) and stalk antibody titers 
(14.2% to 9.8%), respectively (Table 2.2). 
We completed several experiments to validate our HA stalk IgG data. Headless 
H1 proteins are engineered to possess only the HA stalk domain and not the HA globular 
head domain [273]. We completed experiments with mAbs to verify that HA stalk-reactive 
antibodies bind to headless H1 proteins in ELISAs. We found that the H1 head-specific 
EM-4C04 mAb bound efficiently to a full-length H1 HA protein but failed to bind to our 
headless H1 protein, while the H1 stalk-specific 70-1F02 mAb bound to each construct 
similarly (Figure 2.2). We used two additional methods to verify that headless HA-based 
ELISAs accurately quantify HA stalk-reactive Abs. First, we measured antibody binding to 
a full-length HA chimeric protein that possessed an exotic head domain from an H6 virus 
fused to the H1 stalk (abbreviated c6/H1) [319]. Since H6 viruses have never circulated in 
the human population, most human antibodies that bind to this recombinant HA target the 
HA stalk domain [304]. We found similar relative HA stalk antibody levels when we used 
the c6/H1 HA-based ELISAs instead of headless HA-based ELISAs (Figure 2.2). We also 
quantified HA stalk antibody levels using a competition ELISA. For these experiments, we 
determined the amount of serum antibodies that was required to prevent the binding of a 
biotinylated HA stalk-specific mAb (70-1F02). The 70-1F02 mAb recognizes a 
conformationally dependent epitope that spans the HA1 and HA2 subunits [147, 148, 283, 
284, 310]. We found that 70-1F02-based competition assay titers correlated strongly with 




Assessment of HA stalk-specific serum antibody isotypes 
Some HA stalk antibodies mediate protection through non-neutralizing 
mechanisms that involve processes such as ADCC [167]. IgG1 and IgG3 antibody 
subtypes are efficient at inducing ADCC, whereas IgG2 and IgG4 are not [320]. We 
quantified relative IgG1, IgG2, and IgG3 HA stalk antibodies in serum from a subset of 
participants using ELISAs coated with headless H1 proteins. In all participants, the 
majority of HA stalk IgGs were IgG1 (Figure 2.3), consistent with previous reports [162, 
321]. HA stalk IgG1 antibody titers were slightly higher in uninfected participants than in 
infected participants (Figure 2.3). Total HA stalk IgG titers closely correlated with HA stalk 
IgG1 titers (Figure 2.3). Undetectable levels of IgG2 and very low levels of IgG3 HA stalk 
antibodies were detected in serum (Figure 2.3). We did not measure levels of IgG4 HA 
stalk antibodies, since previous studies have shown that IgG4 is not prevalent among anti-
influenza virus human antibodies [162]. It is important to note that titers of each isotype 
are directly comparable in our experiments, since we used control mAbs in each ELISA 
(based on the CR9114 HA stalk mAb [322, 323]) that were engineered to possess the 
same variable regions coupled to different constant regions. 
We next evaluated serum HA stalk IgA Abs, since IgA antibodies can be important 
for controlling respiratory infections. For example, mucosal IgA potently reduces the risk 
of influenza transmission events in guinea pigs in a dose-dependent manner [324] and 
suppresses the extracellular release of virus from infected cells [325]. Further, anti-HA 
stalk mAbs engineered on an IgA backbone neutralize virus more effectively than when 
they are engineered on an IgG backbone [326]. We did not have access to respiratory 
secretions, but we did measure levels of HA stalk monomeric IgA in the serum from a 
subset of participants. Similar to HA stalk IgG1 titers (Figure 2.3), we found that serum HA 
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stalk IgA titers were slightly higher in uninfected participants than in infected participants 
(Figure 2.3). IgG1 and IgA titers were moderately, though significantly, correlated (Figure 
2.3). 
Functionality of antibodies from infected and uninfected individuals 
Antibodies against the HA head and HA stalk can neutralize or limit virus 
replication through distinct mechanisms [147, 164, 165, 167, 168, 283, 286, 327, 328]. For 
example, most antibodies that target epitopes near the receptor binding domain of the HA 
head block virus binding and neutralize virus in vitro and in vivo [327]. Some HA stalk 
antibodies can directly neutralize virus, but the majority of HA stalk antibodies require Fc 
receptor engagement for protection in vivo [167, 284, 329]. Neutralizing HA stalk 
antibodies typically inhibit HA conformational changes required to mediate fusion of the 
virus and cellular membranes [147, 165, 283, 286]. Other HA stalk antibodies can prevent 
subsequent viral expansion at later stages of infection by inhibiting HA maturation [165] 
and viral egress [164]. 
We completed experiments to assess the in vitro and in vivo protective potential of 
serum antibodies from a subset of infected and uninfected individuals. First, we 
performed in vitro neutralization assays using green fluorescent protein (GFP)-reporter 
influenza viruses [330]. We generated H1N1 viruses possessing genes encoding 
enhanced GFP (eGFP) in place of most of the PB1 gene segment. The eGFP segment 
retained the noncoding and 80 terminal coding nucleotides, allowing this segment to be 
efficiently and stably packaged into virions. Neutralization assays were completed with 
these viruses in cell lines that stably expressed PB1. We detected in vitro neutralization 
titers in serum from approximately half of the participants that we tested. We found that in 
vitro neutralization titers were significantly higher in the uninfected group than in the 
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infected group by Welch’s t test (Figure 2.4). As expected, serum samples with the highest 
HAI titers had high in vitro neutralization titers (Figure 2.4), whereas serum samples with 
the highest HA stalk titers had more variable in vitro neutralization titers (Figure 2.4). 
We next completed in vitro ADCC assays using serum from a subset of 
participants. As controls, we also tested mAbs against the HA stalk (CR9114) and HA 
head (EM-4C04). For these assays, we incubated HA-expressing 293T cells with serum 
and then added human peripheral blood mononuclear cells (PBMCs). We then measured 
CD107a (LAMP1) expression on CD3− CD56+ NK cells by flow cytometry. CD107a is a 
sensitive NK cell degranulation marker whose expression levels strongly correlate with 
cytokine production and cytotoxicity by NK cells in response to Ab-Fc receptor 
engagement [331]. Consistent with previous studies [322], the CR9114 HA stalk mAb 
activated NK cells more efficiently than the EM-4C04 HA head mAb (Figure 2.4). Serum 
samples from participants also activated NK cells, but importantly, we found no differences 
between NK activation in sera from infected and that from uninfected individuals (Figure 
2.4). 
Finally, we completed passive transfer experiments in mice. For these experiments 
we passively transferred human sera into mice that have been engineered to possess 
human Fc receptors [332] so that we could accurately assess the protective effects 
mediated by human Fc-FcR interactions. We passively transferred pooled sera from 
uninfected individuals that had high (>40) HAI titers (abbreviated as uninfected HAIhigh) 
and uninfected individuals that had low (≤40) HAI titers (abbreviated as uninfected HAIlow). 
We also passively transferred pooled sera from infected individuals, all of whom had low 
(≤40) HAI titers (abbreviated as infected HAIlow). For these experiments, equal volumes of 
human sera were transferred for each experimental condition. Mice were challenged with 
a sublethal dose of H1N1 4 hours after serum transfer, and body weights were monitored 
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for 15 days (Figure 2.5). Mice that received sera from uninfected HAIhigh participants were 
fully protected against H1N1 infection. Mice that received sera from HAIlow participants, 
whether from uninfected or infected individuals, were moderately protected against H1N1 
infection, although these sera conferred significantly less protection than sera from 
HAIhigh participants (Figure 2.5 and Table 2.3).  
Since there were different amounts of HA antibodies in sera from uninfected HAIhigh 
participants, uninfected HAIlow participants, and infected participants (Figure 2.5), it is 
unclear if the differences in our passive transfer experiments were due to differences in 
overall HA antibody titers or differences in HA head and stalk antibody ratios. To address 
this, we repeated passive transfer experiments after adjusting serum amounts so that 
equal amounts of HA antibodies were passively transferred in each experimental group. 
Similar to what we found in our initial passive transfer experiment, sera from uninfected 
HAIhigh participants protected mice better than sera from uninfected HAIlow participants and 
infected participants (Figure 2.5 and Table 2.4). Interestingly, sera from uninfected 
HAIlow participants protected mice better than sera from infected participants after 
adjusting serum amounts based on HA antibody titers (Figure 2.5 and Table 2.4). Taken 
together, these data suggest that human sera with high HAI activity efficiently protect in 
vivo, while human sera with low HAI activity also protect in vivo, albeit to a lower extent. 
 
Section 2.4 - Discussion 
Observational studies can be useful in identifying antibody types that are 
associated with protection from influenza virus infection. Here, we found that both HA head 
and stalk antibodies appeared to be associated with preventing H1N1 hospitalizations 
during the 2015–2016 season. We found that the effect size of HAI-associated protection 
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(23.4% reduced risk of infection for every 2-fold increase in titer) was larger than the effect 
size of HA stalk Ab-associated protection (14.2% reduced risk of infection for every 2-fold 
increase in titer). In our study, HAI titers were independently associated with protection in 
adjusted models; however, HA stalk antibodies were not. However, the effects of both HAI 
and HA stalk antibody titers were only slightly attenuated in our adjusted model, and it is 
possible that our relatively small sample size limited our ability to detect an independent 
association between HA stalk titers and protection. 
There are several limitations to our study. Since our sample size was relatively 
small, we only evaluated the contribution of antibodies to the HA head and stalk. Larger 
studies will be required to independently evaluate other immune correlates of protection. 
For example, it will be important for future studies to evaluate the relationship between HA 
head and stalk antibody-associated protection and neuraminidase (NA) Ab-associated 
protection. Recent studies have shown that NA antibodies are associated with protection 
in an H1N1 challenge cohort [313], and NA antibodies were also identified as an 
independent correlate of protection in a controlled vaccine efficacy study [143]. It will be 
critical to determine if NA Ab-associated protection is independent of the protective effects 
of HA head and stalk Abs. 
It should be noted that participants in our study were likely admitted to the hospital 
at various days post-infection. While most blood specimens were collected relatively early 
(≤3 days after symptom onset), we cannot exclude that some participants in our studies 
were infected for a prolonged period of time before being admitted to the hospital. This 
raises the possibility that some participants have already mounted de novo antibody 
responses to H1N1 infection, which could convolute the analyses of antibody types 
associated with protection. While this is a possibility, it is less of a concern since we found 
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that all infected individuals have very low HAI titers. If our infected participants were 
making de novo antibody responses, we would anticipate that some of them would have 
high HAI titers to the infecting H1N1 virus. In addition, antibody titers do not typically 
increase as days from symptom onset to blood specimen collection increases [318], which 
suggests that samples used in this study were collected prior to the generation of de 
novo antibody responses against the infecting virus. 
It is interesting that in vitro neutralization titers (Figure 2.4), but not ADCC titers 
(Figure 2.4), were associated with H1N1 protection. In vitro neutralization activity is mainly 
driven by HA head antibodies [133, 298-301], whereas HA stalk antibodies are more 
effective at ADCC [167]. It should be noted that HA stalk IgG1 and IgA antibodies have 
been shown to mediate phagocytosis with innate cellular partners [173], which could prove 
to be an important mechanism of protection by HA stalk antibodies and should be 
considered in future studies. HA head antibodies were associated with greater protection 
in our cohorts than stalk antibodies (Table 2.4), and these antibodies conferred protection 
superior to that of HA stalk antibodies when passively transferred into mice (Figure 2.4). 
Interestingly, serum from HAIlow uninfected participants protected mice better than serum 
from HAIlow infected participants in passive transfer studies after normalizing total HA 
antibody amounts under each transfer condition. While these data suggest that HA stalk 
antibodies can confer protection in vivo, we cannot rule out that other immune components 
(such as NA Abs) contributed to protection in these experiments. 
Taken together, our findings provide important new insights into the prevalence 
and functionality of HA head and stalk antibodies in humans. Future studies that tease out 
the interdependence of HA head and stalk antibodies, as well as antibodies and T cells 
against other viral antigens, will be useful in guiding the development of new universal 
influenza vaccine antigens. 
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Section 2.5 - Materials and Methods 
Human subjects: During the 2015–2016 influenza season, adult (≥18 years) patients 
hospitalized for treatment of acute respiratory illnesses at the University of Michigan 
Hospital in Ann Arbor, MI, and Henry Ford Hospital in Detroit, MI, were prospectively 
enrolled in a case test-negative design study of influenza vaccine effectiveness. All 
participants provided informed consent and were enrolled ≤10 days from illness onset 
during the period of influenza circulation (January to April of 2015 and 2016). Participants 
completed an enrollment interview and had throat and nasal swab specimens collected 
and combined for influenza virus identification. Influenza vaccination status was defined 
by self-report and documentation in the electronic medical record and Michigan Care 
Improvement Registry (MCIR). When available, clinical serum specimens collected as 
early as possible after hospital admission were retrieved; all specimens were collected 
≤10 days from illness onset based on the enrollment case definition. Studies involving 
humans were approved by the Institutional Review Boards of the University of Michigan 
and University of Pennsylvania. All experiments (HAI, ELISAs, in vitro neutralization 
assays, ADCC assays, and passive transfers) were completed at the University of 
Pennsylvania using deidentified sera. 
Viruses: Viruses possessing A/California/07/2009 HA and NA or A/HUP/04/2016 HA and 
NA were generated by reverse genetics using internal genes from A/Puerto Rico/08/1934. 
Viruses were engineered to possess the Q226R HA mutation, which facilitates viral growth 
in chicken eggs. Viruses were grown in fertilized chicken eggs, and the HA gene was 
sequenced to verify that additional mutations did not arise during propagation. We isolated 
the A/HUP/04/2016 virus from respiratory secretions obtained from a patient at the 
Hospital of the University of Pennsylvania in 2016. For this process, deidentified clinical 
material from the Hospital of the University of Pennsylvania Clinical Virology Laboratory 
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was added to Madin-Darby canine kidney (MDCK) cells (originally obtained from the 
National Institutes of Health) in serum-free medium with l-(tosylamido-2-phenyl) ethyl 
chloromethyl ketone (TPCK)-treated trypsin, HEPES, and gentamicin. Virus was isolated 
from the infected MDCK cells 3 days later. We extracted viral RNA and sequenced the HA 
gene of A/HUP/04/16. 
Recombinant HA proteins: Plasmids encoding the recombinant headless HA stalk were 
provided by Adrian McDermott and Barney Graham from the Vaccine Research Center at 
the National Institutes of Health. The headless HA stalk protein was expressed in 293F 
cells and purified using nickel-nitrilotriacetic acid agarose (no. 1018244; Qiagen) in 5-ml 
polypropylene columns (no. 34964; Qiagen), washed with pH 8 buffer containing 50 mM 
Na2HCO3, 300 mM NaCl, and 20 mM imidazole, and then eluted using pH 8 buffer 
containing 50 mM Na2HCO3, 300 mM NaCl, and 300 mM imidazole. Purified protein was 
buffer exchanged into phosphate-buffered saline (PBS; no. 21-031-CM; Corning). 
Following purification, the headless HA stalk proteins were biotinylated using the Avidity 
BirA-500 kit (no. BirA500) and stored in aliquots at −80°C. Plasmids encoding the 
recombinant chimeric (c6/H1) HA were provided by Florian Krammer (Mt. Sinai). The 
detailed protocol for expression of this protein is published elsewhere [319]. In brief, the 
c6/H1 HA protein was expressed in High Five baculovirus cells and purified using the 
same methods referenced for the headless HA stalk protein. Purified protein was buffer 
exchanged into PBS (no. 21-031-CM; Corning) and stored in aliquots at −80°C. 
MAbs: Plasmids encoding the human mAb EM-4C04, 70-1F02, and CR9114 IgG1 
isotypes were provided by Patrick Wilson at the University of Chicago. The heavy-chain 
constant regions for IgG2, IgG3, and IgA (sequences listed below) were synthesized as a 
gBlock by IDT and cloned into the pSport6 vector containing the heavy chain of CR9114. 
All mAbs were expressed in 293T cells and purified 4 days postinfection using NAb protein 
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A/G spin kits (no. 89950; Thermo Fisher) for the IgG isotypes or using peptide M agarose 
(no. gel-pdm-2; InvivoGen) for the IgA isotype. 


































































HAI assays: Serum samples were pretreated with receptor-destroying enzyme (no. 
370013; Denka Seiken) followed by hemadsorption, in accordance with WHO 
recommended protocols [333]. HAI titrations were performed in 96-well U-bottom plates 
(no. 353077; Corning). Sera were initially diluted 2-fold and then added to four 
agglutinating doses of virus, for a final volume of 100 μl/well. Turkey erythrocytes (no. 
7209401; Lampire) were added to each well (12.5 μl diluted to 2%, vol/vol). The 
erythrocytes were gently mixed with sera and virus and then allowed to incubate for 1 h at 
room temperature. Agglutination was read and HAI titers were expressed as the inverse 
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of the highest dilution that inhibited four agglutinating doses of virus. Each HAI assay was 
performed independently on two different days. 
Headless HA ELISAs: Headless HA ELISAs were performed on 96-well Immulon 4HBX 
flat-bottom microtiter plates (no. 3855; Thermo Fisher) coated with 0.5 μg/well of 
streptavidin (no. S4762; Sigma). We completed total IgG headless HA ELISAs with all 
serum samples and isotype headless HA ELISAs with serum samples that had sufficient 
volumes. Biotinylated headless HA protein was diluted in biotinylation buffer containing 1× 
Tris-buffered saline (TBS; no. 170-6435; Bio Rad), 0.005% Tween (no. 170-6531; Bio 
Rad), and 0.1% bovine serum albumin (no. A8022; Sigma) to 0.25 μg/ml, and 50 μl was 
added per well and incubated on a rocker for 1 h at room temperature. Each well was then 
blocked for an additional 1 h at room temperature using biotinylation blocking buffer 
containing 1× TBS (no. 170-6435; Bio Rad), 0.005% Tween 20 (no. 170-6531; Bio Rad), 
and 1% bovine serum albumin (no. A8022; Sigma). Each serum sample was serially 
diluted in biotinylation buffer (starting at 1:100 dilution for total IgG or 1:50 dilution for 
antibody isotype), added to the ELISA plates, and allowed to incubate for 1 h at room 
temperature on a rocker. As a control, we added the human CR9114 stalk-specific mAb, 
starting at 0.03 μg/ml, to verify equal coating of plates and to determine relative serum 
titers. Peroxidase-conjugated goat anti-human IgG (no. 109-036-098; Jackson), 
peroxidase-conjugated mouse anti-human IgG1 (no. 9054-05; Southern Biotech), 
peroxidase-conjugated mouse anti-human IgG2 (no. 9060-05; Southern Biotech), 
peroxidase-conjugated mouse anti-human IgG3 (no. 9210-05; Southern Biotech), or 
peroxidase-conjugated goat anti-human IgA (no. 2050-05; Southern Biotech) was 
incubated for 1 h at room temperature on a rocker. Finally, SureBlue TMB peroxidase 
substrate (no. 5120-0077; KPL) was added to each well, and the reaction was stopped 
with the addition of 250 mM HCl solution. Plates were extensively washed with PBS (no. 
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21-031-CM; Corning) and 0.1% Tween 20 (no. 170-6531; Bio Rad) between each step 
using a BioTek 405 LS microplate washer. Relative titers were determined using a 
consistent concentration of the CR9114 mAb for each plate and reported as the 
corresponding inverse of the serum dilution that generated the equivalent optical densities 
(OD). Each type of ELISA (total IgG, IgG1, IgG2, IgG3, and IgA) was performed twice. 
Chimeric (c6/H1) HA ELISAs: Chimeric HA ELISAs were performed on 96-well Immulon 
4HBX flat-bottom microtiter plates (no. 3855; Thermo Fisher). HA proteins were diluted in 
PBS (no. 21-031-CM; Corning) to 2 μg/ml and coated at 50 μl per well overnight at 4°C. 
Plates were blocked using an ELISA buffer containing 3% goat serum (no. 16210-064; 
Gibco), 0.5% milk (no. DSM17200-1000; Dot Scientific, Inc.), and 0.1% Tween 20 (no. 
170-6531; Bio Rad) in PBS (no. 21-031-CM; Corning) 1× for 2 h at room temperature. 
Each serum sample was serially diluted in the ELISA buffer (starting at 1:100 dilutions), 
added to the ELISA plates, and allowed to incubate for 2 h at room temperature. As a 
control, we added the human CR9114 stalk-specific mAb, starting at 0.03 μg/ml, to verify 
equal coating of plates and to determine relative serum titers. Peroxidase-conjugated goat 
anti-human IgG (no. 109-036-098; Jackson) next was incubated for 1 h at room 
temperature. Finally, SureBlue TMB peroxidase substrate (no. 5120-0077; KPL) was 
added to each well, and the reaction was stopped with the addition of 250 mM HCl 
solution. Plates were extensively washed with PBS (no. 21-031-CM; Corning) and 0.1% 
Tween 20 (no. 170-6531; Bio Rad) between each step using a BioTek 405 LS microplate 
washer. Relative titers were determined using a consistent concentration of the CR9114 
mAb for each plate and reported as the corresponding inverse of the serum dilution that 
generated the equivalent OD. Each ELISA was performed twice. 
Competition ELISAs: Competition ELISAs were performed on 96-well Immulon 4HBX 
flat-bottom microtiter plates (no. 3855; Thermo Fisher). HA proteins were diluted in 1× 
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Dulbecco’s PBS (DPBS; no. 21-031-CM; Corning) to 2 μg/ml and coated at 50 μl per well 
overnight at 4°C. Plates were blocked using the biotinylation blocking buffer, described 
earlier, for 2 h at room temperature. Each serum sample was serially diluted in biotinylation 
buffer (starting at 1:10 dilution), added to the ELISA plates, and allowed to incubate for 1 
h at room temperature before adding human 70-1F02 mAb (specific for the 
conformationally dependent HA stalk epitope 1 [334]) that had been biotinylated using the 
Invitrogen SiteClick biotin antibody labeling kit (no. S20033; Thermo Fisher) at a constant 
concentration of 0.03 μg/ml and incubated at room temperature for an additional hour. As 
a control, we added the human CR9114 stalk-specific mAb, starting at 0.03 μg/ml, to verify 
equal coating of plates and to determine relative serum titers. Peroxidase-conjugated 
streptavidin (no. 554066; BD Pharmingen) next was incubated for 1 h at room 
temperature. Finally, SureBlue TMB peroxidase substrate (no. 5120-0077; KPL) was 
added to each well, and the reaction was stopped with the addition of 250 mM HCl 
solution. Plates were extensively washed with PBS (no. 21-031-CM; Corning) and 0.1% 
Tween 20 (no. 170-6531; Bio Rad) between each step, with the exception of the addition 
of biotinylated 70-1F02, using a BioTek 405 LS microplate washer. Relative titers were 
determined using the uncompeted control lane OD (biotinylated 70-1F02 binding in the 
absence of sera) and setting that OD to 100%. Each serum sample was then assessed 
by nonlinear regression using GraphPad Prism. Titers are reported as the inverse of the 
highest serum dilution that inhibited binding of the biotinylated 70-1F02 to 30% of the 
uncompeted binding. Each competition ELISA was performed independently on two 
different days. 
In vitro neutralization assays: In vitro neutralization assays were completed using a 
subset of samples. We excluded samples that had limited amounts of sera. Plasmids 
encoding pH1N1 viruses possessing genes encoding eGFP in place of most of the PB1 
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gene segment were provided by Jesse Bloom at The Fred Hutchinson Cancer Research 
Center. The eGFP segment retained the noncoding and 80 terminal coding nucleotides, 
allowing this segment to be efficiently and stably packaged into the virions. Detailed 
protocols for the reverse genetics, expression, and in vitro neutralization assays using the 
recombinant viruses have been published elsewhere [330, 335]. In brief, serum was 
pretreated with receptor-destroying enzyme (no. 370013; Denka Seiken) and then serially 
diluted in neutralization assay medium (Medium 199; no. 11150-059; Gibco) 
supplemented with 0.01% heat-inactivated fetal bovine serum (FBS; no. F0926-100; 
Sigma), 0.3% bovine serum albumin (no. A8022; Sigma), 100 U penicillin–100 μg 
streptomycin/ml (no. 30-002-Cl; Corning), 100 μg of calcium chloride/ml (no. S7653; 
Sigma), and 25 mM HEPES (no. 25-060-Cl; Corning), beginning at a 1:80 dilution. 
PB1flank-eGFP viruses were then added to the serum dilutions and were incubated at 
37°C for 1 h to allow for neutralization. As a control, the human CR9114 HA stalk-specific 
mAb was added to ensure equal infectivity and neutralization across all plates. Viruses 
and sera then were transferred to 96-well flat-bottom tissue culture plates containing 
80,000 cells per well of MDCK-SIAT1-TMPRSS2 cells constitutively expressing PB1 under 
a cytomegalovirus promoter. Plates were incubated at 37°C for 30 h postinfection. Mean 
fluorescent intensity of samples was read using an Envision plate reader (monochromator, 
top read, excitation filter at 485 nm, emission filter at 530 nm). Neutralization titers were 
reported as the inverse of the highest dilution that decreased mean fluorescence by 90% 
relative to infected control wells in the absence of antibodies. Each neutralization assay 
was performed independently on two different days. 
ADCC activity assays: ADCC activity assays were completed using a subset of samples. 
We excluded samples that had limited amounts of sera. 293T cells were plated at 3.5e4 
cells per well in a 96-well flat-bottom tissue culture plate (no. 353072; Corning) 24 h before 
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transfection. 293T cells were then transfected using 20 μl Opti-MEM (no. 31985-070; 
Gibco), 1 μl Lipofectamine 2000 (no. 11668-019; Invitrogen), and 500 ng plasmids 
encoding the HA gene from A/California/07/09 per well and incubated at 37°C for 
approximately 30 h before performing the ADCC assay. Approximately 12 h before 
performing the ADCC assay, frozen PBMCs from four separate donors (obtained through 
the University of Pennsylvania Human Immunology Core) were thawed at 37°C and then 
washed 3× using 15 ml of warmed complete RPMI medium (no. 10-040-CM; Corning) 
(supplemented with 10% heat-inactivated FBS [no. F0926-100; Sigma], 1% penicillin-
streptomycin [no. 30-002-Cl; Corning]). Each aliquot of PBMCs was then transferred to a 
50-ml conical tube and rested overnight in 23 ml of complete RPMI medium at a 5° angle, 
with the cap loosened to allow for gas exchange. On the day of the assay, serum samples 
were diluted in Dulbecco’s modified Eagle’s medium (no. 10-013-CM; Corning) 
supplemented with 10% FBS (no. F0926-100; Sigma) at a 1:10 dilution. As a control for 
this assay, the human CR9114 HA stalk-specific mAb was included at a concentration of 
5 μg/ml to ensure efficient activation of ADCC. Transfected 293T cells were loosened by 
pipetting and transferred to a 96-well U-bottom plate (no. 353077; Corning) and spun down 
for 1 min at 1,200 rpm, and the medium was flicked out. The serum/mAb dilutions were 
transferred to the plates containing the transfected 293T cells and were mixed with the 
transfected cells by gentle pipetting and incubated at 37°C for 2 h. PBMC aliquots were 
combined, spun down, and counted, and a master mix of 2e7 cells/ml was set up using 
complete RPMI medium. Aliquots of the PBMC master mix were set up for the live/dead 
and unstained control wells. Phycoerythrin-conjugated mouse anti-human CD107a (no. 
328608; BioLegend) was added at a 1:50 dilution. Brefeldin A (no. B7651; Sigma) was 
added to 10 μg/ml. Monensin (no. 51-2092KZ; BD BioSciences) was added to 5 μl per 1 ml 
of PBMC master mix concentration. An aliquot of 200 μl was made, phorbol myristate 
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acetate (no. P1585; Sigma) was added to a 5 μg/ml concentration, and ionomycin (no. 
I9657; Sigma) was added to a 1 μg/ml concentration. Serum/cell suspensions were spun 
down at 1,200 rpm for 1 min, and medium was flicked out. The PBMC master mix and the 
aliquots for the various controls were plated at 50 μl per well and mixed gently by pipetting, 
followed by incubation at 37°C for 4 h. Cells were then stained in the following manner. 
Live/dead fixable near-infrared stain (no. L34976; Thermo) was diluted 1:50 in DPBS (no. 
21-031-CM; Corning) and 1% bovine serum albumin (no. A8022; Sigma) for 30 min in the 
dark at 4°C. Human FcR blocking reagent (no. 130-059-901; Miltenyi Biotec) was diluted 
1:25 in DPBS (no. 21-031-CM; Corning) and 1% bovine serum albumin (no. A8022; 
Sigma) and incubated in the dark for 10 min at 4°C. Alexa Fluor 647-conjugated mouse 
anti-human-CD3 (no. 344826; BioLegend) and BV421-conjugated mouse anti-human 
CD56 (no. 318328; BioLegend) were diluted 1:200 in DPBS (no. 21-031-CM; Corning) 
plus 1% bovine serum albumin (no. A8022; Sigma) and incubated in the dark for 30 min 
at room temperature. Cells were then fixed using 10% paraformaldehyde (no. 15714-S; 
Electron Microscopy Sciences) diluted in MilliQ water for 6 min at room temperature. Cells 
were extensively washed with DPBS (no. 21-031-CM; Corning) and 1% bovine serum 
albumin (no. A8022; Sigma) between each step. Cells were stored overnight at 4°C in 
100 μl/well of DPBS (no. 21-031-CM; Corning) and 1% bovine serum albumin (no. A8022; 
Sigma). Flow cytometry was performed using and LSRII (BD Biosciences, San Diego, 
CA). Compensation controls were set up using anti-mouse Igκ beads (no. 552843; BD 
BioSciences) and run for each antibody for every experiment, and voltages were adjusted 
accordingly. All data were analyzed in FlowJo (Ashland, OR) by gating on single cells that 
were CD3− CD56+ CD107a+in control wells that did not contain serum/mAb to adjust for 
basal levels of CD107a expression. These gates were then applied to each serum sample, 
and ADCC activity was expressed as a percentage of NK cells expressing CD107a+. Each 
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ADCC assay was performed independently on three different days, and the same four 
PBMC donors were pooled and used for each replicate. 
Murine experiments: All mouse experiments were reviewed and approved by the 
IACUCs of the Wistar Institute and University of Pennsylvania. All passive transfer 
experiments were performed in humanized FcR mice (hFcgR [1, 2a, 2 b, 3a, 3b]tg+/mFcgR 
alpha chain [1, 2 b, 3, 4]−/−) that were provided by Jeffrey Ravetch at the Rockefeller 
University [332]. Sera were pooled into three groups, uninfected HAIhigh(>40 HAI titer), 
uninfected HAIlow (≤40 HAI titer), and infected HAIlow (≤40 HAI titer), and then heat treated 
for 30 min at 55°C. Serum or sterile PBS was then transferred into mice by intraperitoneal 
injection. Four hours posttransfer, mice were bled by submandibular puncture, 
anesthetized using isoflurane, and challenged intranasally using 50 μl of sterile PBS 
containing a sublethal dose (9e4 50% tissue culture infective dose units) of 
A/California/07/09. ELISAs were run on the sera collected from each animal to verify that 
the passive transfer was successful. Mice were weighed on the day on infection and then 
daily for 15 days postinfection. Weight loss was reported as percent weight loss relative 
to the starting weight of each mouse. For the passive transfer normalized by volume, two 
independent experiments were performed using a mix of male and female humanized FcR 
mice for a total of 6 mice per group per experiment. For the passive transfer normalized 
by HA antibody titer, a single experiment was performed using a mix of male and female 
humanized FcR mice for a total of 6 mice per group, since we had limited amounts of sera 
available for this study. One-way analysis of variance (ANOVA) was performed for each 
day postinfection between groups using GraphPad Prism software. 
Statistical analysis: Fisher’s exact tests, one-way ANOVAs, and Welch’s t tests were 
completed using GraphPad software. Both unadjusted and adjusted logistic regression 







Figure 2.1. Assessment of HA head and stalk antibody association with protection. 
(A) HAI assays were completed using sera from uninfected (gray) and infected (red) 
individuals. HAI titers are associated with protection against H1N1 infection (P = 0.0108, 
logistic regression of log2 geometric mean titers from two independent experiments). (B) 
ELISAs using headless HA constructs were completed using sera from uninfected (gray) 
and infected (red) individuals. HA stalk-specific antibodies are associated with protection 
against influenza infection (P = 0.0417, logistic regression analysis using log2 geometric 
mean titers from two independent experiments). (C) HA head antibodies measured by HAI 
and HA stalk titers measured by ELISA using headless HA stalk constructs are weakly, 
though significantly, correlated (r = 0.2778, P = 0.0002, Spearman correlation using 
log2 geometric mean titers from two independent experiments for each measurement). In 








Figure 2.2. Validation of headless H1 HA stalk construct. We completed additional 
ELISAs using the 70-1F02 HA stalk mAb and the EM-4C04 HA head mAb and plates 
coated with headless HA (A) or full-length HA (B). Graphs depict representative results 
from two independent experiments. (C) We quantified HA stalk antibodies using ELISA 
plates coated with c6/H1 proteins. HA stalk titers measured by ELISA using c6/H1 or 
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headless HA stalk constructs were tightly correlated (r = 0.7776, P < 0.0001, Spearman 
correlation using log2 geometric mean titers from two independent experiments). (D) We 
completed competition assays using the conformationally dependent 70-1F02 mAb. 70-
1F02 competition titers are tightly correlated with overall HA stalk antibody titers in both 
infected and uninfected individuals (r = 0.9097, P < 0.0001, Spearman correlation using 
log2geometric mean titers from two independent experiments). In panels C and D, each 


























Figure 2.3. Assessment of HA stalk-specific serum antibody isotypes. (A) ELISAs 
were completed to quantify the levels of IgG1, IgG2, IgG3, and IgA HA stalk antibodies in 
each serum sample. Higher titers of HA stalk-specific IgG1 and IgA were present in 
uninfected individuals but not in infected individuals (P = 0.0180 and P = 0.0426, 
respectively, by Welch’s t test using log2-transformed mean titers from two independent 
experiments). (B) IgG1 HA stalk antibody titers closely correlated with total IgG HA stalk 
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antibody titers (r = 0.9184, P < 0.0001, Spearman correlation using log2 geometric mean 
titers from two independent experiments). (C) IgA HA stalk antibody titers moderately 
correlated with IgG1 HA stalk antibody titers (r = 0.3500, P < 0.0001, Spearman correlation 
using log2geometric mean titers from two independent experiments). In all panels, each 









Figure 2.4. In vitro functionality of HA antibodies from infected and uninfected 
individuals. (A) In vitro neutralization assays were completed with sera from uninfected 
and infected individuals. In vitro neutralization titers are significantly higher in uninfected 
than infected participants (P = 0.0026, Welch’s t test using log2mean titers from two 
independent experiments). Neut90, neutralization titer at which the inverse of the highest 
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dilution decreased mean fluorescence by 90% relative to infected control wells in the 
absence of antibodies. (B) HAI titers correlate strongly with neutralization titers 
(r = 0.5073, P < 0.0001, Spearman correlation using log2 geometric mean titers from two 
independent experiments). (C) HA stalk titers also correlate with neutralization titers 
(r = 0.4574, P < 0.0001, Spearman correlation using log2 geometric mean titers from two 
independent experiments). (D) ADCC assays were completed using sera from uninfected 
and infected individuals. Assays were also completed using the CR9114 and EM-4C04 
mAbs. As negative controls, we completed ADCC assays using 293T cells without HA or 
293T cells with HA but without Ab. ADCC activity is not significantly different between the 
uninfected and infected participants (P = 0.9538, Welch’s t test using log2 mean titers from 









Figure 2.5. HA head and stalk antibodies confer protection from severe disease in 
vivo. (A) Passive transfer experiment design and timeline. Sera were stratified by HAI titer 
and infection status, pooled, and transferred intraperitoneally to humanized Fc-receptor 
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mice 4 h before challenge with A/California/07/2009. Weights were measured daily for 
15 days. (B) We transferred equal volumes of sera into each mouse for our initial 
experiments. Mice that received uninfected HAIhigh sera were completely protected against 
infection (gray line). Mice that received HAIlow sera (uninfected or infected, blue and red 
lines, respectively) were also protected but were significantly less protected than the mice 
that received HAIhigh sera (results are given with ± standard errors of the means [SEM]; 1-
way ANOVA was performed for each day postinfection based on percent weight lost 
relative to starting weight using two independent experiments with 6 mice/group; results 
are listed in Table 3). (C) We completed ELISAs to quantify total H1-reactive antibodies in 
each of our pooled serum samples and found that there were different amounts of HA 
antibodies in each serum pool. (D) We repeated passive transfer studies after normalizing 
serum amounts so that equal amounts of HA antibodies were transferred. Mice that 
received uninfected HAIhigh or uninfected HAIlow pooled sera (gray and blue lines, 
respectively) were protected similarly against severe influenza disease, with mice that 
received uninfected HAIhigh pooled sera recovering more quickly than mice that received 
uninfected HAIlow pooled sera (results are given with ±SEM; 1-way ANOVA was performed 
for each day postinfection based on percent weight lost relative to starting weight using 








Table 2.1. Demographic characteristics of subjects enrolled in hospital-based 








Table 2.2. Logistic regression modeling of HA head and stalk antibody association 
with protection. Logistic regression analyses using both unadjusted (HAI only and stalk 
only) and adjusted (HAI plus stalk) models. Values represent log2 geometric mean titers 
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Section 3.1 - Abstract 
An H1N1 virus caused an influenza virus pandemic in 2009 and has continued to circulate 
seasonably in humans over the past decade. Upon infection with the 2009 H1N1 strain, 
many humans produced antibodies against epitopes in the hemagglutinin (HA) stalk. HA 
stalk-focused antibody responses were common among 2009 H1N1-infected individuals 
because HA stalk epitopes were conserved between the 2009 H1N1 strain and previously 
circulating H1N1 strains. Here, we completed a series of experiments to determine if high 
levels of H1N1 HA stalk antibodies within the human population has led to antigenic drift 
in the H1N1 HA stalk since 2009. We identified 6 amino acid substitutions that have 
accrued in the H1N1 HA stalk since 2009. We completed enzyme-linked immunosorbent 
assays, absorption-based binding assays, and surface plasmon resonance experiments 
to determine if these substitutions affect antibody binding. Using sera collected from 230 
humans (aged 21-80 years), we found that H1N1 HA stalk substitutions that have emerged 
since 2009 do not dramatically affect antibody binding. Our data suggest that the HA stalk 












Section 3.2 - Introduction 
Influenza pandemics typically occur when a novel influenza strain crosses the 
species barrier into human circulation and transmission. The limited immunological 
memory within the population allows for unhindered spread of the novel virus, resulting in 
pandemic-level morbidity and mortality rates [336]. Even after the population develops 
robust immunity against the pandemic virus, it can continue to circulate seasonally by 
evading previously elicited antibody (Ab) responses through the accumulation of 
mutations in the viral membrane proteins hemagglutinin (HA) and neuraminidase (NA), 
through a process called antigenic drift [337]. 
In 2009, a triple reassortment event occurred between H1N1 viruses from avian, 
swine, and human lineages [197]. The novel reassortant precipitated an unusual H1N1 
pandemic – unusual because H1N1 viruses had been continuously circulating seasonally 
in humans since 1977, and had previously circulated in humans from 1918 to 1957 [336]. 
The head domain of the HA protein, the viral membrane protein responsible for viral entry 
into the host cell, of the 2009 pandemic H1N1 (pH1N1) strain contained epitopes that were 
antigenically more similar to the HA from the seasonal H1N1 (sH1N1) strains that 
circulated in humans prior to 1957 [222, 338-340]. However, the HA stalk domain 
remained relatively well-conserved compared to the HA stalk domain of modern circulating 
sH1N1 viruses [338-340]. The conservation of the pH1N1 HA stalk domain resulted in an 
unprecedented boosting of HA stalk antibody responses in humans [219]. The HA stalk 
domain has traditionally been considered immunosubdominant among seasonal influenza 
strains, with the majority of neutralizing antibody responses directed towards the HA head 
[156]. However, monoclonal Abs (mAbs) isolated from individuals exposed to the pH1N1 
strain, through either vaccination or natural infection, target the highly conserved HA stalk 
domain, or the receptor binding site [217, 218, 341]. Most of the isolated mAbs could also 
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bind modern sH1N1 viruses efficiently and demonstrated a high degree of somatic 
mutations, indicating they were secreted from memory B cells recalled during pH1N1 
exposure [217, 218, 341-343]. Many of these HA stalk-specific mAbs neutralized 
antigenically distinct influenza viruses within and across influenza A group 1 and group 2 
viruses [217, 218, 343], and a small number that could neutralize both influenza A and 
influenza B strains [147, 283], in mouse and ferret models.  
The potential for antibodies elicited against the HA stalk domain to confer broad 
neutralization spurred the pursuit of an HA stalk-based universal influenza vaccine. The 
HA stalk domain is an appealing target for a universal influenza vaccine for a number of 
reasons. This domain is more constrained than the HA head, due to the pH-induced 
conformational change required for viral-endosomal membrane fusion and successful 
infection of a host cell [165], and therefore may not be as likely to experience antigenic 
drift, unlike the HA head domain. Additionally, human challenge studies have correlated 
HA stalk antibody titers with reduced viral shedding and number of symptoms [313], and 
serological cohort studies have demonstrated that HA stalk antibodies are significantly 
associated with protection against pH1N1 influenza infection in adults and children [344, 
345].  
Although the amino acid sequence of the HA stalk domain is more constrained 
than the HA head [346], increased immune pressure may drive antigenic drift within this 
domain. Indeed, the H1N1 HA stalk domain is able to undergo antigenic drift in vitro when 
incubated with HA stalk-specific mAbs or human polyclonal serum [347]. The isolated HA 
stalk escape mutants not only replicated well in vitro, but also retained pathogenicity in 
vivo [347]. This is an important finding as it demonstrates greater plasticity in the H1N1 
HA stalk domain and that these escape mutants can retain fitness and virulence, both 
observations that challenge the perception of this domain as an immutable antigenic 
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target. In this study we have harnessed nature’s own experiment of increased 
immunological pressure against the well-conserved HA stalk domain, elicited by pH1N1, 
to determine if antigenic changes have occurred. 
  
Section 3.3 - Results 
Amino acid substitutions have accrued in the H1 HA stalk domain 
We analyzed the HA protein sequences of 2047 H1N1 influenza genomes for 
amino acid substitutions that had gone to fixation in the stalk domain [348, 349]; these 
sequences were obtained from circulating viruses ranging from the introduction of the 
pH1N1 strain in early 2009 through April 2019. A total of seven amino acid substitutions 
were identified (Figure 3.1) that accrued over a span of ten years of seasonal circulation 
(Figure 3.1). Importantly, one of these amino acid substitutions was adjacent to epitope 1, 
the dominant neutralizing epitope in the H1 HA stalk domain (Figure 3.1). 
Amino acid substitutions do not reduce binding by antibodies in human polyclonal 
serum 
Antigenic drift is the accumulation of amino acid substitutions in a viral glycoprotein 
that gradually alters that protein’s antigenicity [350]. Amino acid substitutions in antigenic 
sites of HA can arise as a mechanism to escape antibody neutralization [351], or can be 
stochastically selected by other factors to fine-tune HA function, such as altering pH of 
fusion [352] or viral binding to host receptors [353]. To determine if the amino acid 
substitutions identified in the pH1N1 HA stalk domain had accumulated as the result of 
antigenic drift, we analyzed serum collected from 230 participants enrolled in a household 
cohort study (Ann Arbor, MI, USA) during the 2011-2012 influenza season. Importantly, 
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we selected this seasonal cohort because the majority of individuals would have been 
exposed to the pH1N1 virus (either through natural infection or vaccination), but was 
before the H1-dominated influenza season of 2013-14. Households consisting of at least 
two adults and two children were enrolled prior to the start of the influenza season. Serum 
specimens were obtained for the estimation of H1N1 HA stalk-specific antibody binding to 
the pH1N1 HA stalk domain +/- the identified amino acid substitutions in modern 
circulating H1N1 influenza viruses. 
To test the effect on HA antigenicity of these amino acid substitutions, we 
introduced five of the substitutions (HA1-A13T, HA1-I324V, HA2-E47K, HA2-S124N, and 
HA2-E172K) into a 2009 pH1N1 headless HA stalk protein. The two remaining amino acid 
substitutions (HA1-K283E and HA1-I295V) were not analyzed since the HA1 residues 283 
and 295 sit closer to the HA head and are not in our headless HA construct. We quantified 
relative titers of H1 stalk total IgG antibodies using enzyme-linked immunosorbent assays 
(ELISAs) coated with either the 2009 pH1N1 HA headless stalk protein (abbreviated as 
2009 stalk) or the 2009 pH1N1 HA headless stalk protein containing five amino acid 
substitutions that have gone to fixation (abbreviated as 2019 stalk). We found that HA 
stalk-specific antibodies in polyclonal human serum bound similarly to the 2009 and 2019 
HA stalk constructs, with a relative 2009 stalk mean titer of 3052 and 2019 stalk mean titer 
of 2560 (Figure 3.2). Additionally, the 2009 and 2019 stalk titers were significantly and 
positively correlated (Figure 3.2), suggesting HA stalk antibody binding is not affected by 
the amino acid substitutions.  
We next performed surface plasmon resonance (SPR) with a subset of serum 
samples to determine if the current amino acid substitutions reduced binding affinity (Kd). 
Representative curves and associated relative Kd values are depicted in Figure 3.2 and 
Table 3.1, respectively. We observed a minor decrease in relative KD value for the 2019 
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stalk, compared to the 2009 stalk (Table 3.1). However, all relative Kd values were 100% 
correlated between the 2009 and 2019 stalk (Figure 3.3). Taken together, these results 
indicate that the amino acid substitutions in the H1 HA stalk domain do not alter antibody 
affinity. 
To determine if the slight reduction in HA stalk-specific antibody titers and relative 
Kd values observed in the previous experiments for the 2019 HA stalk were due to true 
alterations in antibody binding, rather than assay-specific variability between the two 
different antigens used, we completed additional absorption assays.  Cells transfected 
with the 2009 or 2019 stalk constructs containing a transmembrane domain were 
incubated with a subset of serum samples to absorb out HA stalk-specific Abs; the 
unbound fraction was then isolated and tested by ELISA against both the 2009 and 2019 
HA stalks. If HA stalk antibody binding was reduced by the presence of the HA 
substitutions in the 2019 stalk, some HA stalk antibodies would remain in the unbound 
fraction of the 2019 absorption, and these could be detected by ELISA against the 2009 
stalk. We quantified HA stalk titers of the unbound fraction of each absorption condition 
against both the 2009 and 2019 HA stalk constructs by ELISA. We observed that both the 
2009 and 2019 stalk efficiently absorbed all HA stalk-specific antibodies from each serum 
sample (Figure 3.4), indicating HA stalk antibody binding is not greatly reduced by the 
amino acid substitutions.  
 
Section 3.4 - Discussion 
The selective forces acting on the HA head and resultant antigenic drift of this 
domain are relatively well-studied [191, 281, 298, 353, 354]. However, much less is known 
about evolution within the HA stalk domain, despite this being a major target for the 
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development of universal influenza vaccine strategies. Sequence alignments reveal that 
circulating H1N1 viruses are accruing amino acid substitutions in the HA stalk domain over 
time (Figure 3.1). However, our data indicates that the presence of these amino acid 
substitutions do not abrogate binding or reduce affinity of HA stalk-specific antibodies in 
human polyclonal serum in a biologically relevant manner (Figures 3.2, 3.3, and 3.4), 
suggesting these substitutions are not selected for immune escape. While it is possible 
these substitutions can simply be attributed to the inherently error-prone function of the 
RNA polymerase, there are two alternative considerations for why these amino acid 
substitutions may have been positively selected. 
Amino acid substitutions can be selected as a means to improve HA function. 
Indeed, one of the HA stalk amino acid substitutions that went to fixation early on, E47K, 
has been closely studied for its effect on viral function [352]. The E47K substitution 
increased both acid and thermal stability in vitro, and also increased pathogenicity in vivo 
[352]. While mechanistic studies have not been conducted on the other amino acid 
substitutions that have arisen in the H1 HA stalk domain, it is possible they also contribute 
to fine-tuning of HA function.  
Another possibility is that these substitutions in the HA stalk arose to compensate 
for antigenic changes within the HA head domain, a mechanism of viral evolution that has 
previously been identified in the highly pathogenic avian influenza virus subtype H5N1 
[355]. Amino acid substitutions that mediate antigenic escape often incur pleiotropic 
effects, such as altered binding to sialic acid, the host cellular receptor for influenza, or 
decreased protein-folding stability [356-361], which in turn decrease viral fitness. In many 
cases viral fitness can only be restored by compensatory mutations in the HA or NA 
proteins that have opposing effects [357-359, 361-364]. Many compensatory mutations 
are neutral and will arise through random drift first [365], thus allowing an otherwise 
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deleterious antigenic mutation to arise, or the two mutations may occur simultaneously. 
As such, the evolution of compensatory mutations can lead to entrenchment, the inability 
of a substitution to revert to its ancestral state without deleterious effects [366].  
While the findings presented in this study do not negate the potential for antigenic 
drift to occur within the HA stalk domain once immunological pressure is increased if HA 
stalk-based universal vaccines are deployed, they do support the HA stalk domain as a 
durable target for a universal influenza vaccine. Future studies should focus on the 
durability of the HA stalk domain after immunization with vaccine platforms designed to 
elicit an HA stalk-specific immune response, as well as the persistence of this response 
in the face of subsequent exposures to similar influenza strains that may revert the 
immune response back towards the immunodominant HA head domain. 
Section 3.5 - Materials and Methods 
Human subjects: During the 2011-2012 influenza season, adult (≥18 years) participants 
were prospectively enrolled in an observational, household cohort design study of 
influenza vaccine effectiveness. All participants provided informed consent and completed 
an enrollment interview. Influenza vaccination status was defined by self-report and 
documentation in the electronic medical record and Michigan Care Improvement Registry 
(MCIR). All specimens were collected prior to the start of the influenza season. Studies 
involving humans were approved by the Institutional Review Boards of the University of 
Michigan and University of Pennsylvania. All experiments (ELISAs, absorptions, and 
surface plasmon resonance) were completed at the University of Pennsylvania using 
deidentified sera. 
Recombinant HA proteins: Plasmids encoding the 2009 H1 HA stalk were provided by 
Adrian McDermott and Barney graham from the Vaccine Research Center at the National 
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Institutes of Health. The sequence from the 2009 H1 HA stalk construct was used to 
design a Gblock of the 2019 H1 HA stalk that incorporated five amino acid substitutions 
(HA1-A13T, HA1-I324V, HA2-E47K, HA2-S124N, and HA2-E172K) +/- a transmembrane 
domain and was ordered from Integrated DNA Technologies. The sequence from the 2009 
H1 HA stalk construct was used again to generate a Gblock containing a transmembrane 
domain attached to the 2009 H1 HA stalk. All Gblocks were cloned into the pSport6 vector 
for expression. The headless HA stalk proteins not containing the transmembrane 
domains were expressed in 293F cells and purified using nickel-nitrilotriacetic acid 
agarose (no. 1018244, Qiagen) in 5-ml polypropylene columns (no. 34964; Qiagen), 
washed with 50 mM Na2HCO3, 300 mM NaCl, and 20 mM imidazole buffer at pH 8. The 
protein was then eluted in 50 mM Na2HCO3, 300 mM NaCl, and 300 mM imidazole buffer 
at pH 8. Purified protein was then buffer exchanged into phosphate-buffered saline (PBS; 
no. 21-031-CM; Corning). Some of each H1 HA stalk protein was aliquoted and stored at 
-80C. The remaining protein was then biotinylated using the Avidity BirA-500 kit (no. 
BirA500) and stored in aliquots at -80C.  
MAbs: Plasmids encoding the human mAb CR9114 were provided by Patrick Wilson at 
the University of Chicago. CR9114 was expressed in 293T cells and purified 4 days post-
infection using NAB protein A/G spin kits (no. 89950; Thermo Fisher). 
Headless HA ELISAs: Headless HA ELISAs were performed on 96-well Immunlon 4HBX 
flat-bottom microtiter plates (no. 3855; Thermo Fisher) coated with 0.5 ug/well of 
streptavidin (no. S4762; Sigma). We completed total IgG headless HA ELISAs (using both 
the 2009 and 2019 stalks) with all serum samples. A detailed protocol has been previously 
described elsewhere [344]. In brief, headless HA stalk proteins were diluted in biotinylation 
buffer to a concentration of 0.25 ug/ml and 50 ul was added to each well. Wells were 
blocked with 150 ul of biotinylation blocking buffer. Serum samples were serially diluted in 
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biotinylation buffer (starting at 1:100 diltiion), then added to the ELISA plates. The human, 
HA stalk-specific mAb CR9114 was used as a plate control, starting at 0.03 ug/ml, to verify 
equal coating of plates and to determine relative serum titers. Peroxidase-conjugated goat 
anti-human IgG (no. 109-036-098; Jackson) was added at 50 ul/well. Finally, SureBlue 
TMB peroxidase substrate (no. 5120-0077; KPL) was added to each well and the reaction 
was quenched with the addition of 25 ul/well of 250 mM HCl solution. Each step was 
incubated for an hour at room temperature on a rocker. Plates were extensively washed 
with PBS (no. 21-031-CM) and 0.1% Tween 20 between each step using a BioTek 405 
LS microplate washer. Relative titers were determined using a consistent concentration of 
the CR9114 mAb for each plate and each HA stalk construct, and reported as the 
corresponding inverse of the serum dilution that generated the equivalent optical densities 
(OD). Each ELISA was performed a minimum of two times. 
Absorption ELISAs: Absorption ELISAs were completed using a randomly selected 
subset of serum samples. 293F cells were split to a 1e6 cells/ml density in 500 mL (160 
ml cell culture volume) vented tissue culture flasks (no. 431145; Corning) on the day of 
transfection. 293F cells were transfected using 1 ml Opti-MEM (no. 31985-070; Gibco), 
320 ul 293Fectin (no. 12347-019; Gibco), and 160 ug plasmids containing the H1 HA stalk 
constructs with a transmembrane domain, or a mock transfection was performed. The 
cells were incubated at 37C, shaking at 800 rpm, for three days. The cells from each 
transfection condition were collected, spun down at 300 xg for 5 minutes, then re-
suspended in 30 mls FreeStyle 293 Expression Medium (no. 12338018; Thermo Fisher). 
An aliquot of cells was taken for counting and the cells were spun again at 300 xg for 5 
minutes, then re-suspended in an appropriate volume of FreeStyle 293 Expression 
Medium (no. 12338018; Thermo Fisher) to obtain a concentration of 1e8 cells/ml. Cells 
and individual serum samples at a 1:10 dilution were mixed in a 1:1.1 ratio (to 
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accommodate for the substantial volume of cells) to ensure a gross excess of antigen was 
present. The serum/cell mixture was incubated in a 96-well U-bottom plate (no. 353077; 
Corning) for 1 hour on a plate shaker set to 800 rpm. The 96-well plate was then 
centrifuged at 2000 RPM for 5 minutes and the supernatant transferred to another 96-well 
U-bottom plate (no. 353077; Corning) and centrifuged a second time for 5 minutes at 2000 
rpm to remove all cells. The supernatant was transferred into labeled microcentrifuge 
tubes (no. 05-408-129; Thermo Fisher) and stored at 4C until a standard headless HA 
ELISA (described above) could be performed. As an absorption control, the human mAb 
CR9114 was incubated under the same absorption conditions at a concentration of 2 
ug/ml. Each absorption ELISA was performed a minimum of two times. 
Surface plasmon resonance. All SPR experiments were performed on the BIACore 
3000 instrument by GE Healthcare. The LS Sensor Chip NTA (no. BR-1004-07; GE 
Health Sciences) surface was conditioned by injecting 350 mM EDTA (diluted from 0.5 
M, pH 8 stock, no. 15575020; Thermo Fisher) at 10 ul/min for 1 minute followed by 
extensive washing with running buffer to remove residual EDTA. To ensure all EDTA 
was removed, a subsequent washing step using 50 mM NaOH, injected at 10 ul/min for 
1 minute was performed. The chip surface was then prepared for antigen capture by 
injecting 0.5M NiCl2 at 10 ul/min for 1 minute. The HIS-tagged 2009 and 2019 HA stalk 
proteins, previously diluted to 2.5 ug/ml in 1x HBS-P buffer (0.01 M HEPES (no. 25-060-
Cl; Corning) pH 7.4, 0.15 M NaCl, 0.005% v/v Polysorbate 20 (Tween 20) (no. BP337-
100; Thermo Fisher)), were immobilized onto separate channels of the LS Sensor Chip 
NTA (no. BR-1004-07; GE Health Sciences) at 5 ul/min with a target density of 350 
response units, followed by a 20 minute incubation. Serum samples, previously diluted 
to concentrations of 1:100, 1:400, and 1:1600 in 1x HBS-P buffer, were injected at 20 
ul/min for 150 seconds over the immobilized rHA stalk chip channels or the reference 
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chip channel, followed by a 400s dissociation phase. Each step was followed by an 
extensive washing cycle using 1x HBS-P buffer. For kinetic analysis, injections over 
reference cell channels and injections with buffer only were subtracted from the data. 
Association rates (ka), dissociation rates (kd), and equilibrium dissociation constants (Kd) 
were calculated by aligning the curves to fit a Langmuir 1:1 binding model using 
BIAevaluation 4.1 software. To obtain a relative concentration of H1 HA stalk-specific 
antibodies in each polyclonal serum sample used, we performed an HA stalk ELISA 
(according to methods described above) to determine the serum dilution required to 
achieve an OD equivalent to 2 nM of CR9114. These relative serum concentrations were 
used as input for the Langmuir 1:1 model for each serum sample concentration. Each 




























Figure 3.1. Amino acid substitutions have accrued in the HA stalk domain.  Analysis 
of entropy at each amino acid position in 2047 H1N1 HA genomes from 2009 - 2019 using 
Nextstrain.org. (A) Seven amino acid substitutions have entered fixation in the seasonal 
H1N1 HA stalk domain. Black outline depicts location of epitope 1. (B) Timeline of when 










Figure 3.2. Amino acid substitutions do not greatly reduce binding by antibodies in 
human polyclonal serum. Relative H1 HA stalk titers for the 2009 and 2019 headless 
HA stalk constructs were determined by ELISA. Each dot represents a single serum 
sample (n = 230). (A) Relative mean stalk titers are 3052 and 2560 for the 2009 and 2019 
H1 HA stalk domain, respectively. (B) 99.47% of samples demonstrated <2-fold difference 
in titers between the 2009 and 2019 H1 HA stalks. The ratio of the titers (2009/2019) were 
determined using geometric mean titers of two independent experiments. (C) Relative 
titers between the 2009 and 2019 HA stalk are strongly and significantly correlated 






























Figure 3.3. Amino acid substitutions do not decrease affinity of H1 HA stalk-specific 
antibodies in human polyclonal serum. A subset of serum samples (n = 16) were 





plasmon resonance (SPR). (A) Representative serum sample binding and dissociation 
curves by SPR (blue line = 2009 stalk, red line = 2019 stalk). (B) All samples demonstrated 
<2-fold difference in relative Kd values between the 2009 and 2019 H1 HA stalks. The 
ratios of the titers (2009/2019) were determined using geometric mean Kd values of two 
independent experiments. Each dot represents a single serum sample. (C) Relative Kd 
values for the 2009 and 2019 stalks demonstrated highly significant correlation (Spearman 
correlation, r2 = 1.00, p < 0.0001). Correlation was performed on geometric mean titers of 




























Figure 3.4. Amino acid substitutions in the H1 HA stalk domain do not decrease 
absorption efficiency of antibodies from human polyclonal serum. H1 HA stalk titers 
for the 2009 and 2019 headless HA stalk constructs were determined by ELISA. (A) 
Unbound fraction of serum was isolated post-absorption with either the 2009 or 2019 
headless HA stalk constructs, or with mock transfected cells. HA stalk titers for the 2009 
and 2019 absorption conditions are depicted as % area under the curve (AUC) relative to 
the mock absorption condition. All titers were below the limit of detection in the 2009 and 






























Table 3.1. Relative Kd values for H1 HA stalk-specific antibodies in human 
polyclonal serum. Relative concentrations of H1 HA stalk-specific antibodies were 
determined by ELISA using a standard curve generated from the H1 HA stalk-specific 
mAb CR9114. Each serum sample was assessed by surface plasmon resonance (SPR) 
against the 2009 and 2019 headless HA stalk. Relative Kd values represent the geometric 
mean value of two independent experiments.  




CONCLUSIONS AND FUTURE DIRECTIONS 
 
Section 4.1 - Summary 
Influenza viruses are a persistent threat to public health, and our current vaccine 
strategy is not consistently effective in protecting the population from the considerable 
morbidity and mortality of seasonal influenza infections. We have been in a continual ‘arms 
race’ since the first influenza vaccine was developed in the 1940s. The cycle of creating 
a vaccine based on circulating viral strains that undergo antigenic drift, followed by 
updating those vaccines and the rise of new antigenic variants, has continued for over 
seventy years. The problem is that our current vaccine strategy elicits antibodies that 
primarily target a protein domain that is formidable in its ability to retain functionality while 
constantly altering its form through antigenic drift. Additionally, the strain-specific HA head 
antibodies induced by seasonal influenza vaccines are not expected to protect against 
novel influenza viruses that jump into human circulation through reassortment events. The 
influenza field has been diligently working to address this problem since the 1970s, with 
the goal of developing a universal influenza vaccine that can provide protection against 
drifted seasonal strains and potential pandemic strains alike.  
The approach to developing a universal influenza vaccine sounds deceptively 
simple: identify a viral protein that is highly constrained between influenza A strains and 
develop a vaccine platform that will elicit antibodies against that protein. However, to 
successfully develop a more persistent and broadly protective vaccine, we must consider 
not only the immunogenicity of a viral target, but also investigate the polyclonal antibody 
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response against target candidates to understand how immune history affects the 
dynamics of immune responses, as well as the durability of antibody-mediated protection 
against these targets.  
In Chapter 2 we demonstrated for the first time that HA stalk antibody titers are 
associated with protection against influenza infection and severe disease, though the 
protective effect size was smaller than that of HA head antibodies (Figure 2.1 and Table 
2.2). Despite their association with protection, we were unable to identify a clear threshold 
of protection for HA stalk antibody titers, which will be an important consideration in the 
future for use as a surrogate marker of protection. However, this lack of a clean cutoff 
between uninfected and infected individuals can also occur with HA head antibody titers 
[367], even though the HAI titer of >1:40 is the widely accepted threshold of protection 
[241, 242]. As discussed in Chapter 1, identifying true correlates of protection is difficult 
and we often have to turn to surrogate serological markers, such as antibody titers. The 
caveat with ELISA titers, though specific for the HA stalk domain, is that we are simply 
measuring prevalence, rather than functionality. However, we also demonstrated that 
polyclonal serum from individuals with low HA head antibody titers was able to confer 
moderate protection against severe disease in mice when challenged with pH1N1, 
demonstrating the functionality of the HA stalk antibodies quantified by ELISA. This is an 
important component of establishing a true correlate of protection and should be 
considered in future studies to assess HA stalk antibody titers as a surrogate marker of 
protection. Importantly, a study was published shortly after ours using a much larger cohort 
that supported our findings and demonstrated the independent association of HA stalk 
antibodies with protection against influenza infection in both adults and children [345]. 
Finally, we determined that the overall ratio of HA stalk antibody isotypes is fairly similar 
between uninfected and infected individuals in pre-infection serum. However, we found 
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that uninfected individuals have significantly higher titers of serum IgG1 and IgA antibodies 
compared to infected individuals (Figure 2.3). Given that different antibody isotypes are 
associated with different Fc-receptor mediated effector functions, a prevailing functional 
characteristic of HA stalk antibodies, this observation warrants further investigation.  
Once we determined that HA stalk antibodies were associated with protection 
against influenza infection, we turned our attention to the possibility for antigenic drift 
within the HA stalk domain. Exposure to the 2009 pH1N1 strain caused the preferential 
boosting of HA stalk-specific antibodies in many individuals [218, 219, 287], providing a 
natural experiment to determine if increased immune pressure against this domain would 
generate amino acid substitutions in the HA stalk domain. In Chapter 3 we hypothesized 
that amino acid substitutions would have accumulated in the H1 HA stalk since 2009, and 
that these substitutions would affect the antigenicity of this domain. We identified seven 
amino acid substitutions in the HA stalk domain of the 2019 H1N1 strain relative to the 
2009 pH1N1 strain (Figure 3.1), when this viral lineage was originally introduced into 
humans. We engineered headless HA stalk constructs from the 2009 and 2019 H1N1 
viruses to use as tools to elucidate if the amino acid changes were antigenically relevant, 
using polyclonal human sera. We found that the overall binding and specific affinities of 
HA stalk antibodies were not decreased in a biologically relevant manner by the amino 
acid substitutions present in the 2019 HA stalk (Figures 3.2, 3.3, and 3.4), suggesting the 
HA stalk domain has not experienced antigenic drift in its ten-year history of human 
circulation. This conclusion is highly relevant to the development of current HA stalk-based 
universal influenza vaccines, as it demonstrates the HA stalk is a durable target for long 
term antibody-mediated immunity.  
These two projects revealed new, supporting evidence for the HA stalk domain as 
a desirable candidate for a universal influenza vaccine. These findings also provide new 
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avenues for basic research into the functional characteristics of HA stalk antibody isotypes 
and consequences of amino acid substitutions for non-neutralizing stalk antibodies, as 
well as translational investigations on the induction of HA stalk antibodies to protective 
thresholds and effects of immune history on induction. This chapter will focus on the 
broader implications of our work for the development of an HA stalk-based universal 
influenza vaccine and the future directions of both projects. 
 
Section 4.2 - Protective immune responses against the HA stalk domain 
There is still much to learn about the induction and functionality of HA stalk 
antibodies, as well as the need to establish correlates of protection that can be reliably 
tested in a high through-put manner. In this section I will address each of these outstanding 
areas of research and potential avenues of investigation to move towards the ultimate goal 
of developing a truly universal influenza vaccine. 
HA stalk antibody titers as a novel correlate of protection 
In Chapter 2 we demonstrated that HA stalk antibody titers are associated with 
protection against influenza infection in humans as measured by ELISA. However, it is 
imperative that we develop novel, reliable assays to quantify the protective effects of HA 
stalk antibodies and an associated titer that can be used as a surrogate marker for a true 
correlate of protection. Agencies responsible for immunization recommendations, such as 
the US Advisory Committee for Immunization Practices and the World Health 
Organization, rely on established thresholds of surrogate markers as an immunological 
correlate to differentiate between individuals considered to be immunologically protected 
versus susceptible [368, 369]. In terms of vaccine development, demonstration of an 
immunological correlate for candidate vaccines is quickly becoming a fundamental 
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objective in clinical trials and epidemiological studies, so a protective threshold for HA 
stalk antibodies may be required for future HA stalk-based universal influenza vaccine 
trials. Determination of a protective threshold for HA stalk antibody titers can be used as 
an indicator for successful seroconversion in vaccine trials and will simplify clinical trials 
of the vaccine in new populations, such as age- and risk-groups, by providing an 
immunogenicity endpoint that can help avoid the need of a large-scale efficacy trial. 
Identification of an HA stalk antibody correlate is also important for the comparison of old 
(seasonal) to new (universal stalk-based) vaccines, as well as assessment of the duration 
of protection conferred by these vaccines. Ultimately, an established protective threshold 
will be a crucial component for the success and licensure of HA stalk-based universal 
influenza vaccines. Additionally, the FDA offers accelerated approval for applications that 
include correlates that are deemed “reasonably likely” to predict clinical benefits [370].  
As previously mentioned, current seasonal influenza vaccines elicit strain-specific 
antibodies that target the HA head domain and are quantified using HAI assays. HAI titers 
of 1:40 have been correlated with a 50% reduction in risk of infection [241, 242]. Achieving 
this HAI titer threshold determines successful seroconversion in seasonal influenza 
vaccine trials and is used to demonstrate vaccine effectiveness for the licensing of new 
influenza vaccine platforms [242, 367, 371]. However, HAI assays do not detect antibodies 
that bind to the HA stalk domain. In Chapter 2 we used ELISAs to quantify HA stalk-
specific antibody titers and to demonstrate an association with protection. However, 
ELISAs only measure antigen binding and cannot predict the functionality of these 
antibodies. HA stalk antibodies can mediate protection through several different 
mechanisms, and it is these functional subsets that need to be quantified and used as a 
surrogate marker of protection. The functionality of some HA stalk antibodies may be 
detected through MN studies, but the results will be confounded by the presence of HA 
94 
 
head antibodies when using whole human serum. Some studies have used influenza 
viruses expressing chimeric HAs that have an exotic head domain to detect stalk-only 
neutralization in polyclonal human serum [372], but these results can still be confounded 
by cross-reactive antibodies specific for the highly-conserved RBS of the HA head domain, 
or by antibodies targeting other viral domains. Still other studies have used reporter 
assays to detect Fc-receptor mediated effector functions, such as the NK cell-mediated 
ADCC assay discussed in Chapter 2, or neutrophil-mediated phagocytosis assays [173]. 
The caveat to these types of assays is they each only measure a single function of HA 
stalk antibodies. HA stalk antibodies are often multi-functional and may rely upon the 
presence of their innate cellular partners to realize their full protective potential by 
mediating Fc-receptor effector functions. It is therefore imperative to develop novel, high-
throughput assays or modifications to current assays to quantify the protective effects of 
HA stalk antibodies. This will likely rely upon establishing correlations between in vitro 
functional assay(s), and in vivo protection; ideally, the in vitro assays would detect Fc-
receptor mediated effector functions, as well as traditional neutralization. One approach 
could be the isolation of HA stalk antibodies from human sera that can be used in in vitro 
binding and functionality assays, then correlated with protection in vivo. We are currently 
developing a protocol that will allow fractionation of HA stalk antibodies in human sera: 
serum samples are incubated with streptavidin-coated beads decorated in biotinylated 
‘headless’ HA stalk constructs for the absorption of HA stalk-specific antibodies, the beads 
are isolated and washed, and the HA stalk antibodies are eluted. The HA stalk antibody 
fraction can then be used in traditional functional assays (MN, ADCC, and ADCP) and/or 
passively transferred into mice expressing humanized Fc-receptors. The functional assay 
titers and weight loss from the mouse challenge model could then be correlated. This 
approach would eliminate the confounding presence of neutralizing HA head antibodies 
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in MN assays and would allow simultaneous detection of all protective mechanisms of 
action mediated solely by HA stalk antibodies. While these proposed studies are more 
complex than the current HAI method of detecting seroconversion, they do allow for 
detection of the multi-faceted protection that is mediated by HA stalk antibodies. 
Additionally, if specific surrogate markers from the different functional assays are identified 
as correlating with protection from the in vivo studies, this could establish a simpler, more 
high-throughput means to determine successful seroconversion and to assess vaccine 
effectiveness. 
Induction of protective HA stalk antibody responses 
Although HA stalk antibodies are associated with protection against influenza 
infection, the effect size, or reduction in risk of infection, is ~40% lower for HA stalk 
antibodies as compared to HA head antibodies (Table 2.2). Additionally, polyclonal human 
sera with low HA head antibodies only conferred protection against severe disease, but 
not against infection, when passively transferred into Fc-receptor humanized mice (Figure 
2.5, Tables 2.3 and 2.4). Therefore, a reasonable concern for an HA stalk-based universal 
vaccine is whether or not it can induce functional HA stalk-specific antibodies to titers high 
enough to confer adequate protection against influenza infection in humans. 
HA stalk antibodies can be efficiently elicited by vaccine platforms that redirect the 
immune response towards the immunosubdominant HA stalk domain, using either HAs 
with divergent globular head domains (through chimeric HAs or exposure to exotic avian 
influenza strains) [291, 293, 294, 373] or by removing the HA head completely with a 
headless HA stalk construct [273-275, 292]. Additionally, in vitro ADCC and ADCP assays 
have been used to demonstrate the functionality of HA stalk antibodies induced by these 
methods. However, to tailor vaccines towards the efficient induction of potently 
96 
 
neutralizing and broadly cross-reactive HA stalk-specific immune responses, we should 
carefully examine what drives enhanced immunogenicity of vaccine antigens and consider 
elicitation of cellular immune responses into future vaccine designs.  
Modulation of antigen immunogenicity 
The strategy used for the expression of recombinant proteins used in vaccines is 
an important consideration. Recombinant HA proteins can be prepared from mammalian 
cells, insect cells, bacterial cells, and yeast [168, 374, 375]. Each of these expression 
systems contain different post-translational modification pathways, resulting in different 
levels of glycosylation on the HA protein. Variation in the glycosylation status of the HA 
protein may influence the protective capacity of induced HA stalk-specific antibodies and 
their ability to bind antigen, as glycans on the vaccine antigen may shield neutralizing 
epitopes. A recent study examined the effects of varying numbers of glycosylation sites 
on the antigenicity of an H1 HA stalk protein. This group determined that a mono-
glycosylated HA stalk, expressed in yeast, could induce higher levels of IgG2a antibodies 
in mice that mediated greater ADCC activity, compared to a fully glycosylated H1 HA stalk 
expressed in mammalian cells [376]. Additionally, the neutralization activity of the mono-
glycosylated HA stalk antisera was greater against heterologous H1N1 and H5N1 viral 
strains, compared to the antisera elicited by the fully glycosylated construct [376]. 
Importantly, the binding of antibodies was equivalent between the antisera elicited by the 
mono-glycosylated and fully glycosylated H1 HA stalk. Additionally, the viruses used in 
the neutralization assays would have been fully glycosylated in these assays, as they were 
performed in infected mammalian cells [376]. Taken together, these data indicate that 
mono-glycosylation enhances immunogenicity of the HA stalk domain and the elicited 
antibodies retain their functionality in the presence of a fully glycosylated HA protein. 
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Future work should include in vivo challenge studies, using homologous and heterologous 
strains, in mice previously immunized with either the fully glycosylated or mono-
glycosylated HA stalk. This would determine if the in vitro functionality observed in this 
study correlates with in vivo protection.  
An additional line of study that should be pursued is the difference in glycosylation 
state between Group 1 and Group 2 influenza subtypes. Group 2 HAs, but not Group 1 
HAs, contain a glycosylation site that sits adjacent to the highly conserved epitope 1 
(Figure 1.3) in the HA stalk domain. This glycosylation site has been attributed to the 
difficulties in neutralizing Group 2 influenza subtypes. Therefore, it will be important to 
determine how glycosylation affects the immunogenicity of different HA subtypes, and the 
subsequent functionality of antibodies when faced with a fully glycosylated HA in the 
context of infection. 
Induction of cellular immunity 
In addition to neutralizing antibody responses, HA stalk-specific cellular responses 
also contribute to protective immunity against influenza virus. Mouse studies have 
demonstrated that induction of CD8 T cell responses targeting an epitope in the HA stalk 
domain of the PR8 IAV protects against lethal challenge with heterologous viruses [377]. 
Antibody-independent, antigen-specific CD4 T cells with cytotoxic characteristics have 
also been correlated with viral clearance and decreased disease severity [378-380]. 
Epitopes within the HA stalk domain have been identified that induce cytotoxic, 
polyfunctional CD4 T cells that support a TH1 response through the production of IFN-γ 
and confer partial protection against lethal pH1N1 challenge in mice [381]. Taken together, 
these studies indicate that designing an HA stalk-based universal influenza vaccine that 
can efficiently induce cellular immunity, as well as humoral immunity, may be highly 
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desirable. Indeed, universal influenza vaccines designed to elicit T cell responses to 
augment antibody responses against influenza viral targets have already demonstrated 
robust cross-protective anti-influenza immune responses [382]. However, the risk of 
immunopathology is high when inducing potent effector functions. Since HA stalk 
antibodies can mediate inflammatory effector functions such as ADCC, we must carefully 
consider the implications of intentionally eliciting cytotoxic CD4 and CD8 T cell effector 
functions as well and balance the protective effects against any associated tissue damage 
resulting from such a response.  
Effector functions of HA stalk antibodies 
As discussed in Chapter 1, different antibody isotypes mediate different effector 
functions through variable binding to the Fc-receptors of innate immune cells. In Chapter 
2, we observed that uninfected individuals had elevated titers of serum IgA antibodies 
compared to infected individuals (Figure 2.3). This was an intriguing observation because 
while mucosal anti-influenza IgA titers have been shown to be important in reducing 
transmission events between infected guinea pigs [324] and to inhibit viral egress [325], 
little is known about the contribution of serum IgA antibodies to protection from influenza 
infection. One study revealed that HA stalk-specific IgA antibodies neutralized influenza 
virus more potently than IgG antibodies with identical variable regions, and that memory 
B cells isolated from human peripheral blood were more likely to be stalk-specific when 
secreting IgA antibodies, compared to those secreting IgG antibodies [326]. 
Understanding how antibody isotype contributes to functionality could open the door for 




For example, a recent pre-clinical study for a Mycobacterium tuberculosis (Mtb) 
vaccine reported the use of a liposomal adjuvant that efficiently activates DCs and induces 
a TH1 biased CD4 T cell and antibody response [383]. The study combined the liposomal 
adjuvant with a Mtb protein subunit to evaluate a prime-boost immunization strategy in 
mice, using a combination of parenteral and intrapulmonary administration routes. This 
study provided compelling evidence that this immunization strategy induced high levels of 
antigen-specific IgA and polyfunctional CD4 T cells in both the lung mucosa and in 
systemic circulation [383]. Another example can be found in human immunodeficiency 
virus (HIV) literature. A study using pro-inflammatory cytokines as an adjuvant with an HIV 
peptide antigen, administered intranasally to mice, demonstrated strong induction of 
mucosal and systemic IgA titers [384]. Studies such as these illustrate how vaccines can 
be tailored through the use of adjuvants and routes of administration to induce not only 
specific antibody isotypes that can mediate potent Fc-receptor effector functions, but also 
to direct the immune landscape towards a highly functional TH1 response. 
Fc-receptor mediated effector functions are not regulated solely through antibody 
isotype. Both the isotype and Fc-glycoform composition of an antibody determines which 
Fc-receptor interactions will occur, and thus informs effector functions. The Fc domain of 
antibodies all contain a single biantennary N-glycan attached to the asparagine residue at 
position 297 in the CH2 domain of the heavy chains. The N-glycans are often fucosylated 
and contain a bisecting N-acetylglucosamine (GlcNAc), but vary in the number of antenna 
galactose and sialic acid residues [385]. Fc-glycosylation states of influenza-specific IgG1 
antibodies are altered upon vaccination with seasonal H1N1 in healthy adults and children; 
immunization induced higher levels of galactosylation and sialylation, and decreased the 
levels of bisecting GlcNAc [386]. Importantly, IgG1 Fc N-glycans containing a bisecting 
GlcNAc have been shown to increase ADCC potency in vitro [387, 388], while increased 
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galactosylation has been shown to result in weak Fc-receptor interactions [389]. Taken 
together, these data suggest that current seasonal influenza vaccines result in Fc N-
glycan changes that are inhibitory for Fc-effector functions mediated by anti-influenza 
IgG1 antibodies. In Chapter 2 we observed that IgG1 HA stalk-specific antibodies were 
elevated in uninfected individuals, comprising most of the total IgG response that was 
associated with protection against infection (Figure 2.3). This implies that IgG1 stalk 
antibodies functionally contribute to protection from infection. Considering most HA stalk 
antibodies mediate Fc-effector functions, this could have deleterious consequences for an 
HA stalk-based vaccine. Therefore, it would be beneficial to elucidate the Fc-glycan 
composition on HA stalk-specific antibodies during resting-state and how the Fc-glycan is 
altered with an HA stalk-focused influenza vaccine. Fc-glycan analysis using human or 
murine serum would be fairly straight-forward, as the required tools and reagents are 
readily available. In brief, serum samples could be enriched for HA stalk antibodies 
through the absorption technique described earlier, forgoing the elution step. The Fc 
domain of the antibodies could be isolated by papain digestion (an important step as the 
Fab region of antibodies also contain several N-linked glycosylation sites). The Fc fraction 
could then be treated with PNGase F to cleave the N-linked glycans. Once the Fc-domain 
N-linked glycans are isolated, there are several techniques available for glycan analysis, 
including mass spectrometry, capillary electrophoresis, and HPLC. Glycan standards are 
commercially available. 
As discussed in Chapter 1, the memory B cell repertoire is the primary source of 
HA stalk-specific antibodies [156, 217, 218]. Interestingly, recall of HA stalk-specific 
memory B cells may be advantageous for the N-linked glycosylation state of HA stalk 
antibodies and their mediated effector functions. Memory B cells have lower levels of 
FUT8 expression [390], the enzyme required for adding fucose to the N-linked glycan 
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structure, and therefore may induce higher levels of afucosylated antibodies. Afucosylated 
mAbs have been used therapeutically for many years due to their increased binding affinity 
for FcγRIIIA (CD16) [391], which mediates phagocytosis and ADCC [392], two of the 
primary effector functions induced by HA stalk antibodies. 
 
Section 4.3 - HA stalk domain as a durable target for a universal influenza vaccine 
After determining the H1 HA stalk domain has not experienced antigenic drift in 
the past decade, we posited in Chapter 3 that the amino acid substitutions in the HA stalk 
domain might be compensatory for antigenic changes in the HA head domain. Several 
mutations in the HA head domain that confer binding to human-type receptors have been 
reported to decrease thermal or acid stability of HA, but this stability can be compensated 
for when amino acid substitutions are introduced within the HA stalk domain [355, 393]. It 
has also been shown that HA heat stability and pH of membrane fusion contributes to the 
respiratory droplet transmissibility of influenza viruses in mammals [393, 394]. In this way, 
compensatory mutations that do not themselves alter antigenicity can still contribute to 
increased pathogenicity and even spill-over events that could initiate an influenza 
pandemic. Often, compensatory mutations become “entrenched”, meaning the 
substitution cannot be reverted back to its original state without deleterious effects on viral 
fitness. This potential entrenchment could be exploited to elucidate the compensatory 
nature of the amino acid substitutions in the 2019 H1 HA stalk domain through methodical 
mutational analysis. A panel of single revertants could be assessed for decreased thermal 
and pH stability using simple in vitro assays such as growth curves under different 
temperature conditions and membrane fusions assays, respectively. The library of HA 
stalk revertants could also be assessed for altered receptor binding affinity by surface 
102 
 
plasmon resonance. The determination of the compensatory nature of the accumulated 
H1 HA stalk domain amino acid substitutions will provide a better understanding of the 
evolutionary landscape of influenza virus and may inform future rational vaccine design. 
The HA stalk domain is not static - in Chapter 3 we showed evidence of amino acid 
substitutions that have accrued, albeit slowly, during seasonal circulation (Figure 3.1). 
Additionally, studies have demonstrated that the HA stalk domain can undergo antigenic 
drift in vitro when incubated in the presence of HA stalk-specific mAbs or polyclonal human 
serum [347]. Therefore, it is important to investigate the effects of increased immune 
pressure elicited by HA stalk vaccine candidates on the evolution of the HA stalk domain. 
Although I described the increase in HA stalk antibodies following the 2009 H1N1 
pandemic as “nature’s experiment” to examine the possibility of antigenic drift within the 
HA stalk domain, I have also illustrated in this chapter how the use of adjuvants, 
administration route, and antigen immunogenicity can greatly affect the resulting immune 
response. Therefore, an important consideration regarding the durability of the HA stalk 
domain as a target for a universal influenza vaccine is the potential for antigenic drift to 
occur under the specific immune conditions elicited by a vaccine candidate. This type of 
study would be best performed using a ferret challenge model.  
A ferret challenge model is likely to be a cost-effective and efficient method to 
determine the effects of increased immune pressure on the HA stalk domain in vivo. If a 
ferret model were to be pursued, this type of study should be performed in ferrets that had 
previously recovered from an H1N1 infection, followed by immunization with an HA stalk-
based influenza vaccine; this study design would best recapitulate prior exposure and the 
resultant HA stalk antibody boosting in humans, along with any accompanying immune 
responses elicited by the vaccine candidate. Transmission chains could be set up with the 
ferrets, wherein the first ferret (D0) is infected artificially by nasal inoculation. The D0 
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ferrets could then be co-housed with uninfected ferrets (R0) to create a direct transmission 
line; this would have the added advantage of avoiding direct inoculation of in vitro cultured 
strains, which have previously been shown to alter within-host viral diversity [395]. Once 
the R0 ferret is infected, they can be co-housed with the next recipient ferret (R1). In this 
way, transmission chains (R1-Rx) can be established to allow for multiple passages of the 
virus in the presence of boosted HA stalk antibodies. Ferrets could be sacrificed at each 
stage of the transmission chain, respiratory tissues collected, and the viral HA sequences 
analyzed for evidence of antigenic drift. This approach would allow for a more informed 
and biologically relevant conclusion as to the possibility for antigenic drift within the HA 
stalk domain. 
 
Section 4.4 - Effects of immune history 
An individual’s susceptibility to influenza infection appears to be shaped by their 
very first influenza exposure through immune imprinting, an immune bias towards antigens 
encountered early in life [204, 207, 208]. These initial biases can become more 
entrenched by repeat exposures to diverse influenza antigens through the back-boosting 
of memory B cells, rather than generation of a de novo antibody response [396]. It is 
thought that the HA stalk domain is the driving force behind the group-specific imprinting 
signatures that have been observed in epidemiological studies [208, 397]. Immune 
imprinting can provide immunological benefits by conferring robust protection against 
certain antigenic subtypes, particularly within the same phylogenetic group. Indeed, 
certain birth cohorts have been spared from every modern influenza pandemic, protection 
likely afforded by cross-reactive memory responses primed in childhood [222, 398-402]. 
Additionally, the influenza subtype circulating during a given birth-year can predict an 
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individual’s reduction in risk for severe disease from novel, emerging avian influenza A 
viruses within the same phylogenetic HA group [208].  
Unfortunately, imprinting may have negative consequences as well. For example, 
Gostic et al, demonstrated that 1968, the year when circulating viruses changed from 
Group 1 to Group 2, is a demarcation line for susceptibility to severe disease from 
emerging influenza strains. Individuals born before 1968 would have been imprinted with 
a Group 1 virus, whereas those born after 1968 would likely have been imprinted by a 
Group 2 virus. I highlighted earlier how this birth-year effect predicted reduced risk of 
infection from emerging viruses within the same group, but the inverse is true as well. 
Individuals born before 1968 demonstrated increased risk for severe disease by emerging 
Group 2 viruses, while those born after 1968 were especially susceptible to Group 1 
viruses [208]. Group 1 and Group 2 influenza A viruses have been co-circulating since 
1977, so most individuals have been exposed to both virus sub-groups, suggesting that 
imprinting may hinder the immune system’s ability to mount a strong protective response 
against heterologous influenza viruses encountered later in life. 
The absence of a protective response against influenza strains encountered later 
in life is a concern for the efficacy of an HA stalk-based universal influenza vaccine. It 
suggests that primary influenza exposure may inhibit or dampen the induction of a de novo 
response against influenza exposures to heterosubtypic influenza virus strains. While the 
mechanism behind this has not been fully elucidated, it has been suggested that “epitope 
masking” could play a role [403, 404]. Pre-existing or rapidly secreted antibodies, as in the 
case of a memory response, that recognize conserved stalk domains could sterically 
hinder access to other B cell receptor epitopes; this ‘masking’ could contribute to blocking 
de novo responses against unique, heterosubtypic stalk epitopes. Alternatively, as 
discussed in Chapter 1, the preferential recall of memory B cells generated against 
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influenza strains encountered early in life could be attributed to the lower activation 
threshold of memory B cells and/or to the higher affinity of memory B cells for antigen, 
compared to naïve B cells, resulting in reduced antigen availability for naïve B cells in a 
germinal center response [213]. 
Is there a way to develop a truly universal influenza vaccine, one that provides 
protection against both influenza A groups, if the human immune response is biased 
towards the HA stalk domain of a certain subgroup? In naïve individuals, this could 
potentially be addressed by using a bivalent vaccine containing the HA stalk domains from 
Group 1 and Group 2 viruses; this approach would likely remove the antigenic hierarchy 
and result in a balanced immune response to all included antigens. However, 
seroprevalence for at least one influenza A virus is around 20% by 1 year of age, but 
increases to 99% by 6 years of age [405], indicating vaccination would have to be carried 
out very early in life for this approach to be successful. Unfortunately, for immunologically 
experienced individuals, the immune bias towards the primary influenza strain exposure 
continues to be a real concern. While we could likely tailor the influenza A HA stalk vaccine 
group based on year of birth in an attempt to elicit a response against the strain not 
encountered in childhood (Group 2 for individuals born before 1968 and Group 1 for 
individuals born between 1968-1977), due to the co-circulation of both Group 1 and Group 
2 influenza A viruses in humans, this would not be an option for individuals born after 
1977. 
There are a few avenues that could be pursued to overcome this hurdle of immune 
imprinting. Increasing the dose of a vaccine has proven effective in seasonal vaccines 
designed for the elderly [406, 407], but this would require administering vaccines tailored 
to specific birth-year cohorts based on probability of initial influenza exposure, and so is 
not likely to be an efficient or cost-effective approach. Development of an adjuvanted stalk-
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based vaccine might overcome pre-existing, imprinted immunity. Immunization with an 
AS03-adjuvanted 2009 pH1N1 vaccine readily boosted HA stalk antibody titers, even in 
the presence of high HA head antibody titers against the vaccine strain [408], suggesting 
adjuvants might help circumvent imprinted immune responses. Finally, employing 
unconventional vaccine platforms may improve de novo immune responses, even in the 
presence of high concentrations of pre-existing HA stalk-specific antibodies. One pre-
clinical platform that shows extraordinary promise is the nucleoside-modified, purified 
mRNA lipid nanoparticle (mRNA-LNP) [312, 409]. Protective HA stalk antibody responses 
were efficiently induced in mice, rabbits, and ferrets that were immunized with an mRNA-
LNP encoding for a full-length H1 HA [410]. Since HA stalk antibodies are not efficiently 
induced by seasonal vaccine platforms, which include full-length HA, this would suggest 
the mRNA-LNP platform is capable of directing the immune response towards canonically 
subdominant epitopes, even in the presence of the immunodominant HA head. The 
mRNA-LNP platform has also been shown to induce robust, protective antibody responses 
in the presence of high levels of antigen-specific maternal antibodies in infant mice [411]. 
These results suggest the mRNA-LNP platform may be able to overcome the hurdle of 
decreased antigen availability for a de novo antibody response, or epitope masking, by 
pre-existing antibodies directed against the HA stalk domain. Additional studies are 
required to determine if the mRNA-LNP platform can efficiently induce a de novo response 
in an immunologically experienced individual against heterologous strains in the face of 




Section 4.5 - Criteria for a universal influenza vaccine 
The NIAID recently released a strategic plan for the development of a universal 
influenza vaccine [412]. The strategic plan identifies the criteria that would define a 
universal influenza vaccine. In this final section I will use these criteria to synthesize how 
the work presented here fits into the bigger picture in the pursuit towards an HA stalk-
based universal influenza vaccine. 
Criteria 1: A universal influenza vaccine must be at least 75% effective. 
As discussed in Chapter 2, the protective effect size of HA stalk antibodies is small 
[344], conferring about a 14.2% reduction in risk of infection for every 2-fold increase in 
HA stalk titer (Table 2.2). Investigations into the protective threshold and induction of stalk 
antibodies will help determine if HA stalk antibodies can reach this level of efficacy. 
Additionally, it is important to note that the data presented in Chapter 2 was generated 
using serum samples collected through the Hospitalized Adult Influenza Effectiveness 
Network (HAIVEN), which was created to estimate how effective the seasonal influenza 
vaccine is in preventing severe influenza disease [413]. Most vaccine effectiveness 
networks are focused on primary care cohorts to assess for protection against infection, 
rather than protection against severe disease. It is possible that the protection mediated 
by HA stalk antibodies will not be as effective at protecting against infection in a primary 
care setting. This would be a stumbling block for vaccine approval, as any new vaccine 
would have to demonstrate equivalent or improved effectiveness compared to the current 
seasonal vaccine [414]. 
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Criteria 2: A universal influenza vaccine must be able to protect against both group 
1 and group 2 influenza A viruses. 
In Chapter 1 I described the epitopes of the stalk domain that are conserved to 
varying degrees between influenza A viruses (Figure 1.3). Epitope 1, the conformationally-
dependent epitope that spans the HA1-HA2 interface, is where many of the well-
characterized broadly, neutralizing mAbs bind (Figure 1.3). This epitope is conserved 
across all influenza A viruses, and several human monoclonal antibodies have been 
identified that can neutralize group 1 and group 2 influenza A viruses by binding to this 
epitope [147, 148, 227, 283]. In Chapter 2, we demonstrated that the general population 
has quantifiable levels of serum antibodies that compete for binding to epitope 1 (Figure 
2.2), which suggests that a vaccine aiming to boost memory B cell responses in the 
population that can target this cross-group neutralizing epitope may be a feasible strategy. 
Investigations into the pre- and post-vaccination prevalence of memory B cells that target 
this epitope will be very useful in determining if broadly neutralizing responses can indeed 
be elicited by HA stalk-based vaccine candidates. Additionally, these types of studies 
would determine if targeting this highly conserved cross-group epitope is a way to 
circumvent the difficulty of immune imprinting.  
Criteria 3: A universal influenza vaccine must have durable protection for at least 
one year. 
In Chapter 3 we presented in vitro evidence indicating the H1 HA stalk domain has 
not experienced antigenic drift over the past decade, indicating this domain is a durable 
vaccine target (Figure 3.2, 3.3, and 3.4). However, if an HA stalk-based vaccine is 
deployed, immune pressure will be increased on the HA stalk domain. Therefore, it is 
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important to assess the consequences of boosted HA stalk antibody responses on the 
ability of the HA stalk domain to experience antigenic drift.  
While vaccine platforms have been designed to specifically boost the HA stalk 
antibody response, this domain is still immunosubdominant to the HA head in the context 
of a natural infection. Some evidence suggests that HA head-focused responses can 
overwhelm boosted HA stalk memory responses upon re-exposure to similar strains [156]. 
Therefore, it is important to determine if the prevalence of HA stalk-specific plasma cells 
and memory B cells is maintained in the context of natural infection with influenza strains 
similar to strains previously encountered by that individual. 
Additionally, while the protective potential of Group 2 HA stalk antibodies were not 
addressed in this work, it is important to note that the HA stalk domain of Group 2 HA’s 
seem to have a higher propensity for antigenic drift compared to Group 1 HAs [415]. This 
indicates the HA stalk domain of Group 2 influenza viruses may not be a durable target 
for a universal influenza vaccine, and should be carefully assessed for antigenic drift while 
under increased immune pressure.  
Criteria 4: A universal influenza vaccine must be suitable for all ages. 
Immune imprinting is likely the biggest hurdle for the successful development of a 
truly universal influenza vaccine, regardless of the viral target. We demonstrated that H1 
HA stalk antibody titers were associated with protection in a cohort of individuals, greater 
than 60% of whom were over age 50 and would have likely encountered a Group 1 
influenza virus as their primary exposure (Figure 2.1 and Table 2.1). However, due to the 
immune bias introduced through the primary influenza exposure, it may be difficult to 
induce protective levels of HA stalk antibodies against the Group 2 HA stalk domain. 
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Future work will be required to determine if an HA stalk-based vaccine can overcome this 
imprinting effect, whether through higher doses, adjuvants, or novel vaccine platforms.  
 
Section 4.6 - Concluding remarks 
The pursuit of an HA stalk-based universal influenza vaccine is in full-swing, with 
human clinical trials already underway for two different HA stalk-based platforms. Our 
work has shown that HA stalk antibodies are associated with protection against influenza 
infection and severe disease, and have demonstrated the durability of the H1 HA stalk 
domain as a target for a universal influenza vaccine. However, there are still many 
unanswered questions regarding the induction and cross-group neutralizing potency of 
HA stalk antibodies. It is of the utmost importance to determine the protective threshold of 
HA stalk antibodies to use as an absolute correlate of protection and to develop assays 
that can accurately measure all the protective mechanisms employed by these antibodies. 
These tools and surrogate markers will be the cornerstone for determining 
seroconversion, vaccine efficacy, and immunological endpoints for vaccine trials.  
Finally, I have illustrated how the work presented in this thesis can be integrated 
into future studies addressing the NIAID’s strategic plan for the rational design of a 
universal influenza vaccine. Although the development of a universal influenza vaccine 
will likely be an iterative process, the lessons learned will enhance our understanding of 
the human immune response towards evolutionarily conserved viral targets and how to 
tailor this response through vaccine design to capitalize on the unique functions of these 
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